NZ616762B2 - New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) - Google Patents
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) Download PDFInfo
- Publication number
- NZ616762B2 NZ616762B2 NZ616762A NZ61676212A NZ616762B2 NZ 616762 B2 NZ616762 B2 NZ 616762B2 NZ 616762 A NZ616762 A NZ 616762A NZ 61676212 A NZ61676212 A NZ 61676212A NZ 616762 B2 NZ616762 B2 NZ 616762B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- oligonucleotide
- compound
- nag
- peptide
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 152
- 208000026350 Inborn Genetic disease Diseases 0.000 title claims description 7
- 208000016361 genetic disease Diseases 0.000 title claims description 7
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 title description 21
- 208000037140 Steinert myotonic dystrophy Diseases 0.000 title description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 320
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 97
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims abstract description 40
- 101000701517 Homo sapiens Putative protein ATXN8OS Proteins 0.000 claims abstract description 40
- 102100030469 Putative protein ATXN8OS Human genes 0.000 claims abstract description 37
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims abstract description 21
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 12
- 101000614618 Homo sapiens Junctophilin-3 Proteins 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 69
- 239000002773 nucleotide Substances 0.000 claims description 68
- 208000035657 Abasia Diseases 0.000 claims description 56
- 230000004048 modification Effects 0.000 claims description 56
- 238000012986 modification Methods 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 230000009467 reduction Effects 0.000 claims description 26
- 239000000178 monomer Substances 0.000 claims description 24
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 claims description 18
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 16
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 15
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 230000003274 myotonic effect Effects 0.000 claims description 9
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 8
- NSMOSDAEGJTOIQ-CRCLSJGQSA-N (2r,3s)-2-(hydroxymethyl)oxolan-3-ol Chemical compound OC[C@H]1OCC[C@@H]1O NSMOSDAEGJTOIQ-CRCLSJGQSA-N 0.000 claims description 7
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 claims description 5
- 229940113082 thymine Drugs 0.000 claims description 4
- 102100040488 Junctophilin-3 Human genes 0.000 claims description 3
- 150000003568 thioethers Chemical group 0.000 claims description 3
- KZVAAIRBJJYZOW-LMVFSUKVSA-N (2r,3s,4s)-2-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC[C@H]1OC[C@H](O)[C@@H]1O KZVAAIRBJJYZOW-LMVFSUKVSA-N 0.000 claims 2
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 claims 1
- WROTXLSEMHAZEA-UHFFFAOYSA-N 4-diaminophosphoryloxymorpholine Chemical compound NP(N)(=O)ON1CCOCC1 WROTXLSEMHAZEA-UHFFFAOYSA-N 0.000 claims 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 44
- 238000011282 treatment Methods 0.000 description 42
- 229940024606 amino acid Drugs 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 33
- 239000000074 antisense oligonucleotide Substances 0.000 description 30
- 238000012230 antisense oligonucleotides Methods 0.000 description 30
- 150000002500 ions Chemical class 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- -1 Super T) Chemical compound 0.000 description 21
- 210000003205 muscle Anatomy 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- 229910001868 water Inorganic materials 0.000 description 18
- 239000002105 nanoparticle Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 230000021615 conjugation Effects 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 230000030279 gene silencing Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 13
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 12
- 238000010240 RT-PCR analysis Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 229930010555 Inosine Natural products 0.000 description 11
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 11
- 229960003786 inosine Drugs 0.000 description 11
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 11
- 210000004940 nucleus Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010061533 Myotonia Diseases 0.000 description 10
- 238000000636 Northern blotting Methods 0.000 description 10
- 239000000816 peptidomimetic Substances 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 101100453283 Homo sapiens JPH3 gene Proteins 0.000 description 9
- 229920002873 Polyethylenimine Polymers 0.000 description 9
- 150000008300 phosphoramidites Chemical class 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- GTCDARUMAMVCRO-UHFFFAOYSA-M tetraethylazanium;acetate Chemical compound CC([O-])=O.CC[N+](CC)(CC)CC GTCDARUMAMVCRO-UHFFFAOYSA-M 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 125000002091 cationic group Chemical group 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000003252 repetitive effect Effects 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 7
- 101150112014 Gapdh gene Proteins 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 108010040003 polyglutamine Proteins 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- 229930024421 Adenine Natural products 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229920000155 polyglutamine Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 239000012096 transfection reagent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000003098 myoblast Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IXGZXXBJSZISOO-UHFFFAOYSA-N s-(2-phenylacetyl)sulfanyl 2-phenylethanethioate Chemical compound C=1C=CC=CC=1CC(=O)SSC(=O)CC1=CC=CC=C1 IXGZXXBJSZISOO-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011033 desalting Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000010820 immunofluorescence microscopy Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- VEONRKLBSGQZRU-UHFFFAOYSA-N 3-[6-[6-[bis(4-methoxyphenyl)-phenylmethoxy]hexyldisulfanyl]hexoxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound C1=CC(OC)=CC=C1C(OCCCCCCSSCCCCCCOP(OCCC#N)N(C(C)C)C(C)C)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 VEONRKLBSGQZRU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PKUWKAXTAVNIJR-UHFFFAOYSA-N O,O-diethyl hydrogen thiophosphate Chemical compound CCOP(O)(=S)OCC PKUWKAXTAVNIJR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- XDZLHTBOHLGGCJ-UHFFFAOYSA-N hexyl 2-cyanoprop-2-enoate Chemical compound CCCCCCOC(=O)C(=C)C#N XDZLHTBOHLGGCJ-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001964 muscle biopsy Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108010050934 polyleucine Proteins 0.000 description 3
- 238000002611 posturography Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100034082 Alkaline ceramidase 3 Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 108010002947 Connectin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 101000798828 Homo sapiens Alkaline ceramidase 3 Proteins 0.000 description 2
- 101000901659 Homo sapiens Myotonin-protein kinase Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 102100026260 Titin Human genes 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- JADWVLYMWVNVAN-UHFFFAOYSA-N ctk0h5271 Chemical compound NP(N)(O)=S JADWVLYMWVNVAN-UHFFFAOYSA-N 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- GZWGEAAWWHKLDR-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enoyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)[N+](C)(C)C(=O)CCCCCCC\C=C/CCCCCCCC GZWGEAAWWHKLDR-JDVCJPALSA-M 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 2
- 229950010048 enbucrilate Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102000048595 human DMPK Human genes 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000002071 nanotube Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920000333 poly(propyleneimine) Polymers 0.000 description 2
- 108010054442 polyalanine Proteins 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 229920000575 polymersome Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- QGOKIEUFWNCGFO-UHFFFAOYSA-N propanoic acid;pyrrole-2,5-dione Chemical compound CCC(O)=O.O=C1NC(=O)C=C1 QGOKIEUFWNCGFO-UHFFFAOYSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000022379 skeletal muscle tissue development Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- MUVQIIBPDFTEKM-IUYQGCFVSA-N (2r,3s)-2-aminobutane-1,3-diol Chemical compound C[C@H](O)[C@H](N)CO MUVQIIBPDFTEKM-IUYQGCFVSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
- HLHSUNWAPXINQU-GQCTYLIASA-N (E)-3-(3,4-dihydroxyphenyl)-N-prop-2-ynylprop-2-enamide Chemical compound OC=1C=C(C=CC=1O)/C=C/C(=O)NCC#C HLHSUNWAPXINQU-GQCTYLIASA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- MZLSNIREOQCDED-UHFFFAOYSA-N 1,3-difluoro-2-methylbenzene Chemical compound CC1=C(F)C=CC=C1F MZLSNIREOQCDED-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical class NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- VWSLLSXLURJCDF-UHFFFAOYSA-N 2-methyl-4,5-dihydro-1h-imidazole Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 description 1
- RCZUDMZUWULMID-UHFFFAOYSA-N 2-nitrotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1[N+]([O-])=O RCZUDMZUWULMID-UHFFFAOYSA-N 0.000 description 1
- AUDYZXNUHIIGRB-UHFFFAOYSA-N 3-thiophen-2-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2SC=CC=2)=C1 AUDYZXNUHIIGRB-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ASYBZHICIMVQII-UHFFFAOYSA-N 4-hydroxylysine Chemical compound NCCC(O)CC(N)C(O)=O ASYBZHICIMVQII-UHFFFAOYSA-N 0.000 description 1
- YJHUFZQMNTWHBO-UHFFFAOYSA-N 5-(aminomethyl)-1h-pyrimidine-2,4-dione Chemical compound NCC1=CNC(=O)NC1=O YJHUFZQMNTWHBO-UHFFFAOYSA-N 0.000 description 1
- GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- TVICROIWXBFQEL-UHFFFAOYSA-N 6-(ethylamino)-1h-pyrimidin-2-one Chemical compound CCNC1=CC=NC(=O)N1 TVICROIWXBFQEL-UHFFFAOYSA-N 0.000 description 1
- ZOHFTRWZZPGYIS-UHFFFAOYSA-N 6-amino-5-(aminomethyl)-1h-pyrimidin-2-one Chemical compound NCC1=CNC(=O)N=C1N ZOHFTRWZZPGYIS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000937413 Axia Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- UBDXRTNAPRZXBU-UHFFFAOYSA-N COP1([O-])=[S+]B1 Chemical compound COP1([O-])=[S+]B1 UBDXRTNAPRZXBU-UHFFFAOYSA-N 0.000 description 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000006117 Diels-Alder cycloaddition reaction Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 101100228038 Rattus norvegicus Gapdh gene Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027740 Upper motor neuron dysfunction Diseases 0.000 description 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NHQSDCRALZPVAJ-HJQYOEGKSA-N agmatidine Chemical compound NC(=N)NCCCCNC1=NC(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHQSDCRALZPVAJ-HJQYOEGKSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical class OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000010415 colloidal nanoparticle Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 1
- KKACJTWOOFIGAD-UHFFFAOYSA-N n-carbamoylpropanamide Chemical compound CCC(=O)NC(N)=O KKACJTWOOFIGAD-UHFFFAOYSA-N 0.000 description 1
- GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical class CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical compound SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 description 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- LDWIWSHBGAIIMV-ODZMYOIVSA-M sodium;[(2r)-2,3-di(hexadecanoyloxy)propyl] 2,3-dihydroxypropyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC LDWIWSHBGAIIMV-ODZMYOIVSA-M 0.000 description 1
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical class CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- PCYCVCFVEKMHGA-UHFFFAOYSA-N thiirane 1-oxide Chemical compound O=S1CC1 PCYCVCFVEKMHGA-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical group OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Abstract
Disclosed is a compound comprising a peptide part comprising LGAQSNF linked to an oligonucleotide part comprising (NAG)m in which N is C or 5-methylcytosine, and wherein m is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. Also disclosed is the use of such a compound for the manufacture of a medicament for treating, preventing and/or delaying dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington’s disease-like 2 caused by expansion of CUG repeats in transcripts of the DM1/DMPK, SCA8 or JPH3 genes. ent for treating, preventing and/or delaying dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington’s disease-like 2 caused by expansion of CUG repeats in transcripts of the DM1/DMPK, SCA8 or JPH3 genes.
Description
/050273
New compounds for ng, delaying and/or preventing a human genetic disorder such as
myotonic dystrophy type 1 (DMl)
Field of the invention
The current invention provides new compounds for treating, delaying and/or
ting a human genetic disorder such as DMl.
Background of the invention
Myotonic phy type 1 (DMD is a dominantly ted neuromuscular disorder
with a complex, multisystemic pathology (Harper P.8. et al). DMl is characterized by
expression of DMPK transcripts comprising long CUG repeats, which sequester or
upregulate splice and transcription factors, thereby interfering with normal cellular
function and viability. Antisense oligonucleotide (AON) mediated suppression of toxic
DMPK transcripts is considered a potential therapeutic strategy for this frequent
trinucleotide repeat disorder. The CUG repeat is present in exon 15 of the DMPK
transcript.
The (CUG)n tract itself forms an obvious target, being the only known polymorphism
between mutant and normal-sized transcripts. In a previous study, we identified a 2’-O-
methyl phosphorothioate-modif1ed (CAG)7 oligonucleotide (P858) (SEQ ID NO:1) that is
capable of ng breakdown of mutant transcripts in DMl cell and animal models
(Mulders 8A. et al). For AONs to be ally effective in DMl, they need to reach a
wide variety of tissues, and cell types therein, and be successfully delivered into the nuclei
of these cells. In the t invention, new compounds have been designed based on P858
and comprising a methylated cytosine and/or an abasic site as explained herein, said
compounds have an improved activity, targeting and/or delivering to and/or uptake by
multiple tissues including heart, skeletal and smooth muscle.
and describe oligomers comprising a (CAG)n repeat
unit, such as P858.
Detailed ption of the ion
In a first aspect, there is provided a compound comprising or consisting of
LGAQSNF/(NAG)m in which N, as comprised in the oligonucleotide part (NAG)m is C
(i.e. cytosine) or ylcytosine. Such a compound may be called a conjugate. This
compound comprises a peptide part comprising or consisting of LGAQSNF (SEQ ID
NO:2) which is linked to or coupled to or conjugated with an oligonucleotide part
comprising or consisting of (NAG)m in which N is C or 5-methylcytosine. This compound
could also be named a conjugate. The slash (/) in F/(NAG)m designates the
linkage, coupling or conjugation between the peptide part and the oligonucleotide part of
the compound according to the invention. The peptide part of the compound of the
invention comprises or consists of LGAQSNF. The oligonucleotide part of the compound
of the invention comprises or consists of (NAG)m in which N is C or 5-methylcytosine. In
an embodiment, the compound comprising or consisting of LGAQSNF/(NAG)m in which
N, as comprised in the oligonucleotide part (NAG)m is C or 5-methylcytosine is such that
at least one occurrence of A, as comprised in the oligonucleotide part (NAG)m, ses a
2,6-diaminopurine base modification. The m is ably an integer which is 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.
In a preferred ment, m is 7. Accordingly, a preferred (NAG)m in which N is C or 5-
methylcytosine has a length from 12 to 90 nucleotides, more preferably 12 to 45
nucleotides, even more preferably 15 to 36 nucleotides, most preferably 21 nucleotides.
Said oligonucleotide part preferably comprises at least 15 to 45 utive nucleotides
complementary to a repeat sequence CUG, or at least 18 to 42 utive nucleotides
2O complementary to a repeat sequence CUG, more preferably 21 to 36 nucleotides, even
more preferably 18 to 24 tides, complementary to a repeat sequence CUG.
The compound according to this aspect of the invention may consist of
LGAQSNF/(NAG)m, which means that no other amino acids are present apart from the
LGAQSNF sequence and no other nucleotides are present apart from the repeating NAG
motif atively, the compound can comprise LGAQSNF/(NAG)m, which means that
other amino acids, or analogues or equivalents thereof, may be present apart from the
LGAQSNF sequence and/or other tides, or analogues or equivalents thereof, may be
present at one or at both sides of the repeating NAG motif.
In the context of the present invention, an “analogue” or an “equivalent” of an amino acid
is to be understood as an amino acid which ses at least one modification with
respect to the amino acids which occur naturally in peptides. Such a modification may be a
WO 44906
backbone ation and/or a sugar modification and/or a base modification, which is
further explained and exemplified below.
In the context of the present invention, an “analogue” or an alent” of a nucleotide is
to be understood as a nucleotide which ses at least one modification with respect to
the nucleotides which occur lly in RNA, such as A, C, G and U. Such a modification
may be a backbone modification and/or a sugar modification and/or a base modification,
which is further explained and exemplified below.
In a red embodiment, the oligonucleotide part according to this aspect of the
invention can be represented by L—(X)p—(NAG)m—(Y)q—L, wherein N and m are as defined
above. Each occurrence of L is, individually, a hydrogen atom or the linkage part, coupling
part or conjugation part, as defined further below, connected to or associated with the
peptide part of the compound according to the invention, wherein at least one occurrence
of L is the linkage part, coupling part or conjugation part. In a preferred embodiment, one
occurrence of L is a hydrogen atom and the other occurrence of L is the e part,
coupling part or conjugation part. In another embodiment, both occurrences of L are
hydrogen, and the oligonucleotide is linked, coupled or conjugated to the peptide part via
one of the internal nucleotides, such as via a nucleobase or via an ucleoside e.
Each occurrence of X and Y is, individually, an abasic site as defined further below or a
nucleotide, such as A, C, G, U or an analogue or equivalent thereof and p and q are each
individually an r, preferably 0, l, 2, 3, 4, 5, 6, 7, 8, 9, 10, or higher than 10 or up to
50. Thus, p and q are each individually an integer from O to 50, preferably an integer from
O to 10, more preferably from O to 6. Thus, when p is O, X is absent and when q is O, Y is
absent.
, (X)p—(NAG)m—(Y)q, wherein N and m are as defined above and p and q are 0, is
regarded the oligonucleotide part of a compound according to this aspect of the invention,
wherein its oligonucleotide part ts of (NAG)m. Such an oligonucleotide part
comprising (NAG)m can be represented by (X)p—(NAG)m—(Y)q, wherein N, m, X, Y, p and
q are as defined above and at least one of p and q is not 0.
In a preferred embodiment, p is not 0, and (X)p is represented by (X’)paAG or (X’)pr,
wherein each occurrence of X’ is, individually, an abasic site or a nucleotide, such as A, C,
G, U or an analogue or equivalent thereof, and p’ is p — 2 and p” is p — 1. Such compound
may be represented as:
L—(X’)paAG—(NAG)m—(Y)q—L or
L—(X’)pr—(NAG)m—(Y)q—L.
In an equally preferred embodiment, q is not 0, and (Y)q is represented by NA(Y’)qa or
N(Y’)qw, wherein N is as defined above and each occurrence of Y’ is, individually, an
abasic site or a tide, such as A, C, G, U or an analogue or lent thereof, and q’
is q — 2 and q” is q — 1. Such compound may be represented as:
—(NAG)m—NA(Y’)qa—L or
L—(X)p—(NAG)m—N(Y’)qw—L.
In another preferred embodiment, both p and q are not 0, and both (X)p and (Y)q are
ented by (X’)paAG or (X’)pr and NA(Y’)qa or N(Y’)qw respectively, wherein N, X’,
Y’, p’, p”, q’ and q” are as defined above. Such compound may be represented as:
L—(X’)paAG—(NAG)m—NA(Y’)qa—L,
p»G—(NAG)m—NA(Y’)qa—L,
L—(X’)paAG—(NAG)m—N(Y’ )qw—L, or
L—(X’)pr—(NAG)m—N(Y’)qw—L.
It is to be understood that p’, p”, q’ and q” may not be negative integers. Thus, when (X)p
is represented by AG or (X’)pr, p is at least 1 or at least 2 respectively, and when
2O (Y)q is represented by NA(Y’)qa or N(Y’)q»v, q is at least 1 or at least 2 respectively.
The oligonucleotide part of the compound according to this aspect of the invention can
therefore comprise or consist of one of the following sequences: (NAG)m, AG(NAG)m,
G(NAG)m, AG(NAG)mNA, G(NAG)mNA, NA, AG(NAG)mN, G(NAG)mN, or
(NAG)mN. In an ment, one or more free termini of the oligonucleotide part, i.e. the
terminus where L is hydrogen, may contain 1 to 10 abasic sites, as defined further below.
These abasic sites may be of the same or different types and connected through 3’-5’, 5’-
3’, 3’-3’ or 5’-5’ linkages between each other and with the oligonucleotide part. gh
technically 3’ and 5’ atoms are not present in abasic sites (because of absence of the
nucleobase and thus numbering of atoms that ring), for clarity reasons these are numbered
as they are in the corresponding nucleotides.
In a second aspect, the invention relates to a compound comprising or consisting of the
oligonucleotide sequence (NAG)m, in which N is C or 5-methylcytosine and n at
least one occurrence of N is 5-methylcytosine and/or at least one occurrence of A
comprises a 2,6-diaminopurine nucleobase modification. In a preferred embodiment, all
occurrences of N are 5-methylcytosine. In another preferred embodiment, all occurrences
of A comprise a 2,6-diaminopurine nucleobase. In another red embodiment, all
occurrences of N are 5-methylcytosine and all occurrences of A comprise a 2,6-
diaminopurine nucleobase. In a further preferred embodiment, the nd according to
this aspect of the ion does not comprise a hypoxanthine base or, in other words, an
inosine nucleotide.
The m is preferably an integer, which is preferably 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. In
other words, m is preferably 4 — 15, more ably 5 — 12, and even more preferably 6 —
8. In an especially preferred embodiment, m is 5, 6, 7. The ucleotide comprising
(NAG)m may have a length of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90 nucleotides. In other words, the
oligonucleotide according to this aspect of the invention preferably has a length of 12 to 90
nucleotides, more ably 15 to 49 nucleotides, even more preferably 21 nucleotides.
2O Said oligonucleotide preferably comprises at least 15 to 45 consecutive nucleotides
complementary to a repeat sequence CUG, or at least 18 to 42 consecutive nucleotides
complementary to a repeat sequence CUG, more ably 18 to 36 nucleotides, even
more preferably 18 to 24 nucleotides, complementary to a repeat sequence CUG.
The compound according to this aspect of the invention can be regarded as an
oligonucleotide. Such an oligonucleotide can consist of (NAG)m, which means that no
other nucleotides are present, apart from the repeating NAG motif Alternatively, the
oligonucleotide can comprise (NAG)m, which means that at one or at both sides of the
repeating NAG motif other nucleotides, or ues or equivalents thereof, are present.
In the context of the present invention, an gue” or an alent” of a nucleotide is
to be understood as a nucleotide which comprises at least one modification with respect to
the nucleotides which occur lly in RNA, such as A, C, G and U. Such a modification
WO 44906
may be a backbone modification and/or a sugar modification and/or a base modification,
which is further explained and exemplified below.
Alternatively, the oligonucleotide according to this aspect of the invention can be
represented by H—(X)p—(NAG)m—(Y)q—H, wherein N and m are as defined above. Each
occurrence of X and Y is, individually, an abasic site as defined further below or a
tide, such as A, C, G, U or an analogue or equivalent thereof and p and q are each
individually an integer, preferably 0, l, 2, 3, 4, 5, 6, 7, 8, 9, 10, or higher than 10 or up to
50. Thus, p and q are each individually an integer from O to 50, preferably an integer from
O to 10, more preferably from O to 6. Thus, when p is O, X is absent and when q is O, Y is
absent. The skilled person will appreciate that an oligonucleotide will always start with and
end with a hydrogen atom (H), regardless of the amount and nature of the nucleotides
present in the oligonucleotide.
, H—(X)p—(NAG)m—(Y)q—H, wherein N and m are as defined above and p and q are
0, is regarded a compound according to this aspect of the invention which consists of
(NAG)m. A compound comprising (NAG)m can be represented by H—(X)p—(NAG)m—(Y)q—
H, wherein N, m, X, Y, p and q are as defined above and at least one of p and q is not 0.
In a preferred ment, p is not 0, and (X)p is represented by (X’)paAG or (X’)pr,
wherein each occurrence of X’ is, individually, an abasic site or a nucleotide, such as A, C,
2O G, U or an ue or equivalent thereof, and p’ is p — 2 and p” is p — 1. Such
oligonucleotides may be represented as:
H—(X’)paAG—(NAG)m—(Y)q—H or
H—(X’)p»vG—(NAG)m—(Y)q—H.
In an equally preferred embodiment, q is not 0, and (Y)q is ented by NA(Y’)qa or
N(Y’)qw, wherein N is as defined above and each occurrence of Y’ is, individually, an
abasic site or a nucleotide, such as A, C, G, U or an analogue or equivalent thereof, and q’
is q — 2 and q” is q — 1. Such oligonucleotides may be represented as:
H—(X)p—(NAG)m—NA(Y’ )qa—H or
H—(X)p—(NAG)m—N(Y’)qw—H.
In r preferred embodiment, both p and q are not 0, and both (X)p and (Y)q are
represented by (X’)paAG or (X’)pr and NA(Y’)qa or w tively, wherein N, X’,
Y’, p’, p”, q’ and q” are as defined above. Such oligonucleotides may be represented as:
H—(X’)paAG—(NAG)m—NA(Y’)qa—H,
H—(X’)p»G—(NAG)m—NA(Y’)qa—H,
H—(X’)paAG—(NAG)m—N(Y’ )qw—H, or
H—(X’)pr—(NAG)m—N(Y’)qw—H.
It is to be understood that p’, p”, q’ and q” may not be negative integers. Thus, when (X)p
is represented by (X’)paAG or (X’)pr, p is at least 1 or at least 2 respectively, and when
(Y)q is ented by NA(Y’)qa or N(Y’)q»v, q is at least 1 or at least 2 respectively.
The oligonucleotide according to this aspect of the invention can therefore comprise or
consist of one of the following sequences: (NAG)m, AG(NAG)m, G(NAG)m,
AG(NAG)mNA, G(NAG)mNA, (NAG)mNA, AG(NAG)mN, G(NAG)mN, or (NAG)mN. In
an embodiment, one or more free termini of the oligonucleotide may contain 1 to 10 abasic
sites, as defined further below. These abasic sites may be of the same or different types and
connected through 3’-5’, 5’-3’, 3’-3’ or 5’-5’ linkages between each other and with the
oligonucleotide. Although technically 3’ and 5’ atoms are not present in abasic sites
(because of absence of the base and thus numbering of atoms that ring), for clarity
reasons these are numbered as they are in the corresponding nucleotides.
Whenever (X)p and/or (Y)q comprises one or more abasic sites, this abasic site may be
present at one or both of the termini of the oligonucleotide. Thus, at the 5’-terminus and/or
2O at the 3’-terminus of the ucleotide according to this aspect of the invention, one or
more abasic sites may be present. However, abasic sites may also be present within the
oligonucleotide sequence, as is discussed further below.
An ally preferred oligonucleotide ing to the invention is represented by H—
NAG)m—(Y)q—H, wherein m = 5, 6, 7 and all occurrences ofN are 5-methylcytosine.
An especially preferred oligonucleotide according to the invention is ented by H—
(X)p—(NAG)m—(Y)q—H, wherein m = 5, 6, 7, all occurrences ofN are 5-methylcytosine, p =
q = O and X and Y are .
Another especially preferred oligonucleotide ing to the invention is represented by
—(NAG)m—(Y)q—H, wherein m = 5, 6, 7, all occurrences ofN are 5-methylcytosine,
p = O and q = 4 and all occurrences of Y are abasic sites.
WO 44906
More preferred oligonucleotides of this second aspect have been described in the
experimental part and comprise or consist of SEQ ID NO:16, 17, 19 20.
A preferred oligonucleotide comprises SEQ ID N016 and has a length of 21, 22, 23, 24,
, 26, 27, 28, 29, 30 nucleotides.
Another preferred oligonucleotide comprises SEQ ID NO:17 (21 nucleotides and 4 abasic
sites) and has a length of21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides and the 4 abasic
sites.
Another preferred oligonucleotide comprises SEQ ID NO: 19 or 20 and has a length of 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides.
Oligonucleolide comprising abasic sites
In a third aspect, the present ion relates to a oligonucleotide, which comprises one or
more abasic sites, as defined further below, at one or both i. Preferably 2 to 20, more
preferably 3 to 10, most preferably 4 abasic sites are present at a single terminus of the
oligonucleotide. One or more abasic sites may be present and both free termini of the
oligonucleotide (5’ and 3’), or at only one. The ucleotide according to this aspect of
the invention preferably comprises (NAG)m, wherein N and m are as defined above, and
may further optionally comprise any of the ation as discussed herein, such as one
or more base modification, sugar modification and/or backbone modification, such as 5-
2O methylcytosine, 2,6-diaminopurine, 2’-O-methyl, orothioate, and combinations
thereof.
The oligonucleotide according to this aspect of the invention, comprising one or more
abasic sites at one or both termini has an improved parameter over the oligonucleotides
without such abasic sites as explained later herein..
ucleolide parlor oligonucleotide
In the next section, the ucleotide according to the invention is r defined. This
disclosure is applicable to the oligonucleotide part of the conjugate comprising or
consisting of LGAQSNF/(NAG)m (i.e. first aspect) to the oligonucleotide comprising or
consisting of (NAG)m (i.e. second aspect) and to the oligonucleotide comprising or
consisting of (NAG)m which comprises one or more abasic sites at one or both termini (i.e.
third ) unless explicitly stated otherwise. Thus, throughout the description,
“oligonucleotide according to the ion” can be replaced by either “oligonucleotide
part of the conjugate comprising or consisting of LGAQSNF/(NAG)m” or by
“oligonucleotide comprising or consisting of (NAG)m” or by “oligonucleotide comprising
or consisting of (NAG)m which comprises one or more abasic sites”.
The oligonucleotide according to the invention may have 9 to 90 or 9 to 60 or 9 to 45 or 9
to 42 or 9 to 39 or 9 to 36 nucleotides or 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,
70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90
nucleotides. It is ore clear that the ion also encompasses any specific
oligonucleotide that can be designed by starting and/or finishing at any position in the
given NAG (in which N is C or 5-methylcytosine) without prejudice that one or the other
resulting sequences could be more efficient.
In an embodiment, the oligonucleotide according to the invention or the conjugate
comprising or consisting of LGAQSNF/(NAG)m may further comprise an onal
oligonucleotide part which is complementary to a sequence present in a cell from an
individual to be treated. This onal oligonucleotide part may for e be a
sequence complementary to a sequence flanking the CUG repeat present in the transcript
of a DMl/DMPK (SEQ ID NO: 10), SCA8 (SEQ ID NO: 11) or JPH3 (SEQ ID NO: 12)
gene. Or, this additional oligonucleotide part may for example be a sequence
complementary to a sequence not directly g the repeat sequence CUG in the
transcript of a DMl/DMPK, SCA8 or JPH3 gene. Or, this onal oligonucleotide part
may for e be a sequence complementary to a sequence not directly flanking the
repeat sequence CUG present in the transcript of a DMl/DMPK, SCA8 or JPH3 gene, and
contain a onal motif. Or, this additional oligonucleotide part may for example be a
sequence complementary to a sequence not ly flanking the repeat sequence CUG
present in the transcript of a DMl/DMPK, SCA8 or JPH3 gene, but in proximity because
of the secondary or tertiary structure. Preferably, the sequence (NAG)m in which N is C or
5-methylcytosine is at least 50% of the length of the oligonucleotide ing to the
invention, more preferably at least 60%, even more preferably at least 70%, even more
preferably at least 80%, even more preferably at least 90% or more. In this respect, one or
more abasic sites present at one or both of the termini of the oligonucleotide according to
the invention are not part of the sequence. In a more preferred ment, the
ucleotide according to the invention consists of (NAG)m in which N is C or 5-
methylcytosine. Even more preferably, the oligonucleotide according to the invention
ts of (NAG)m in which N is 5-methylcytosine. Even more preferably, the
oligonucleotide according to the invention ts of (NAG)7 in which N is 5-
methylcytosine.
The oligonucleotide according to the invention may be single stranded or double stranded.
Double stranded means that the ucleotide is a heterodimer made of two
complementary strands, such as in a siRNA. In a preferred embodiment, the
oligonucleotide according to the invention is single stranded. The d person will
tand that it is however possible that a single stranded oligonucleotide may form an
al double stranded structure. However, this oligonucleotide is still named as a single
stranded oligonucleotide in the context of this invention. A single stranded oligonucleotide
has several advantages compared to a double stranded siRNA oligonucleotide: (i) its
synthesis is expected to be easier than two complementary siRNA strands, (ii) there is a
wider range of chemical cations possible to optimise more effective uptake in cells,
a better (physiological) stability and to decrease potential generic adverse effects, (iii)
siRNAs have a higher potential for non-specific effects ding off-target genes) and
exaggerated pharmacology (e.g. less control possible of effectiveness and selectivity by
treatment schedule or dose) and (iv) siRNAs are less likely to act in the nucleus and cannot
be directed against introns.
Different types of nucleic acid monomers may be used to generate the oligonucleotide
according to the invention. The oligonucleotide according to the invention may have at
least one backbone modification, and/or at least one sugar modif1cation and/or at least one
base modif1cation compared to an RNA-based ucleotide.
A base modif1cation includes a modified version of the l purine and pyrimidine bases
(e. g. adenine, uracil, guanine, ne, and thymine), such as hypoxanthine, orotic acid,
agmatidine, lysidine, 2-thiopyrimidine (e.g. 2-thiouracil, 2-thiothymine), 2,6-
opurine, G—clamp and its dervatives, tituted pyrimidine (e. g. 5-halouracil, 5-
methyluracil, 5-methylcytosine, 5-propynyluracil, 5-propynylcytosine, 5-
aminomethyluracil, 5-hydroxymethyluracil, 5-aminomethylcytosine, 5-
hydroxymethylcytosine, Super T), 7-deazaguanine, 7-deazaadenine, 8-azadeazaguanine,
8-azadeazaadenine, 8-azadeaza-2,6-diaminoadenine, Super G, Super A, and N4-
ethylcytosine, or derivatives thereof, and degenerate or universal bases, like 2,6-
difluorotoluene or absent bases like abasic sites (e. g. l-deoxyribose, l,2-dideoxyribose, l-
deoxyO-methylribose, or pyrrolidine derivatives in which the ring oxygen has been
replaced with nitrogen). An oligonucleotide according to the invention may se l, 2,
3, 4, 5, 6, 7, 8, 9, 10 or more base modifications. Examples of derivatives of Super A,
Super G and Super T can be found in US patent 6,683,173 (Epoch ences), which is
incorporated here entirely by reference. It is also encompassed by the invention to
introduce more than one distinct base modification in said oligonucleotide part.
An oligonucleotide according to the ion (i.e. first, second, third aspect) preferably
comprises a modified base and/or an basic site all as fied herein since it is expected to
provide a compound or an oligonucleotide of the invention with an improved RNA binding
kinetics and/or thermodynamic properties, provide a compound or an oligonucleotide of
the invention with a decreased or acceptable level of toxicity and/or genicity,
and/or e pharmacodynamics, pharmacokinetics, activity, allele selectivity, cellular
uptake and/or potential endosomal release of the oligonucleotide or compound of the
invention.
In a more preferred embodiment, one or more 2-thiouracil, 2-thiothymine, 5-
methylcytosine, yluracil, thymine, 2,6-diaminopurine bases is present in said
oligonucleotide according to the invention. As indicated above, the ucleotide
according to the invention which is not conjugated to a peptide part, i.e. the
oligonucleotide as represented by H—(X)p—(NAG)m—(Y)q—H, comprises at least one base
modification selected from 5-methylcytosine (5-methyl-C) and 2,6-diaminopurine. In a
preferred embodiment, the ucleotide according to this aspect of the invention, which
is not conjugated with a peptide part, does not comprise a hypoxanthine base modification.
A sugar modification includes a modified version of the ribosyl moiety, such as 2’-O-alkyl
or 2’-O-(substituted)alkyl (e.g. 2’-O-methyl, 2’-O-(2-cyanoethyl), 2’-O-(2-methoxy)ethyl
(2’-MOE), 2’-O-(2-thiomethyl)ethyl, 2’-O-butyryl, 2’-O-propargyl, 2’-O-allyl, 2’-O-(2-
amino)propyl, 2’-O-(2-(dimethylamino)propyl), 2’-O-(2-amino)ethyl and 2’-O-(2-
hylamino)ethyl)), 2’-deoxy (DNA), 2’-O-alkoxycarbonyl (e. g. 2’-O-[2-
(methoxycarbonyl)ethyl] (MOCE), 2’-O-[2-(N—methylcarbamoyl)ethyl] (MCE) and 2’-O-
[2-(N,N—dimethylcarbamoyl)ethyl] (DCME)), 2’-halo (e.g. 2’-F, FANA (2’-F arabinosyl
nucleic acid)), carbasugar and azasugar modifications; and 3’-O-alkyl (e. g. 3’-O-methyl,
3’-O-butyryl, ropargyl, and derivatives thereof). Another le modification
includes “bridged” or “bicylic” nucleic acid (BNA), e. g. locked nucleic acid (LNA), xylo-
LNA, Ot-L-LNA, B-D-LNA, cEt (2’-O,4’-C constrained ethyl) LNA, cMOEt (2’-O,4’-C
constrained methoxyethyl) LNA, ethylene-bridged nucleic acid (ENA), unlocked nucleic
acid (UNA), cyclohexenyl nucleic acid , altriol nucleic acid (ANA), heXitol c
acid (HNA), fluorinated HNA ), pyranosyl-RNA (p-RNA), 3’-deoxypyranosyl-
DNA (p-DNA), tricyclo-DNA (thNA), lino (PMO), cationic lino
(PMOPlus), PMO-X, and their derivatives. The oligonucleotide according to the invention
may comprise l, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sugar modifications. It is also
encompassed by the invention to introduce more than one distinct sugar ation in
said oligonucleotide.
2O In a preferred embodiment, the oligonucleotide according to the invention comprises at
least one sugar modification selected from 2’-O-methyl, 2’-O-(2-methoxy)ethyl,
morpholino, a bridged nucleotide or BNA, or the oligonucleotide ses both bridged
nucleotides and 2’-deoxy modified nucleotides (BNA/DNA mixmers or gapmers), or both
2’-O-(2-methoxy)ethyl nucleotides and DNA nucleotides (2’-O-(2-methoxy)ethyl/DNA
mixmers or gapmers). More preferably, the oligonucleotide according to the invention is
modified over its filll length with a sugar ation selected from 2’-O-methyl, 2’-O-(2-
methoxy)ethyl, morpholino, d c acid (BNA), 2’-O-(2-methoxy)ethyl/DNA
mixmer, 2’-O-(2-methoxy)ethyl/DNA gapmer, A gapmer or BNA/DNA mixmer.
In an even more preferred embodiment, the oligonucleotide according to the invention
comprises at least one 2’-O-methyl modification. In a more preferred embodiment, an
oligonucleotide according to the invention is fully 2’-O-methyl modified.
In a preferred embodiment, the oligonucleotide according to the invention comprises 1-10
or more monomers that lack the base. Such monomer may also be called an abasic
site or an abasic monomer. Such monomer may be present or linked or attached or
conjugated to a free terminus of the oligonucleotide of the invention.
When the oligonucleotide according to the ion is represented by H—(X)p—(NAG)m—
(Y)q—H, abasic sites may be present within the (X)p portion of the oligonucleotide and/or
the (Y)q portion of the oligonucleotide. When the ucleotide according to the
invention is present within the compound represented by LGAQSNF/(NAG)m, abasic sites
may be present at a free terminus of the oligonucleotide part. These abasic sites may be
present at the terminal regions of the oligonucleotide, i.e. at the minus and/or at the
3’-terminus. Also, the oligonucleotide part of the conjugate may comprise abasic sites.
These abasic site may be attached to a free terminus of said oligonucleotide part of the
conjugate. Because of the conjugation with the peptide part, only one of the termini may be
free. Thus, the 3’-terminus is free when the peptide is conjugated via the 5’-terminus, or
the 5’-terminus is free when the peptide is conjugated via the 3’-terminus. On the other
hand, conjugation with the peptide part may also occur via a nucleotide or other moiety
present within the oligonucleotide part, which leaves both the 5’- and the 3’-terminus free
and thus available for ment of one or more abasic sites.
Apart from the abasic sites present at the free termini of the oligonucleotide according to
2O the invention, abasic sites may also be t within the oligonucleotide sequence. In this
respect, abasic sites are considered base modif1cations.
In a more preferred ment, the oligonucleotide according to the invention comprises
1-10 or more abasic sites or monomers of yribose, 1,2-dideoxyribose, and/or 1-
deoxyO-methylribose. Such r(s) may be present at a free terminus of the
oligonucleotide of the invention. The number of monomers may be 1, 2, 3, 4, 5, 6, 7, 8, 9,
, ll, 12, l3, 14, 15, l6, 17, 18, 19, 20 or even more. Attachment ofa number of these
abasic monomers in an oligonucleotide of the invention shows increased activity with
respect to a control oligonucleotide that does not comprise such monomers. These
monomers may be attached to the 3’ or the 5’ terminal nucleotide, or to both. The abasic
monomers may be attached in regular 5’93’ sequence or ed (3’95’) fashion and
may be linked to each other and to the remainder of the oligonucleotide according to the
invention through ate, orothioate or phosphodiamidate bonds. In a preferred
embodiment, 2-8 abasic sites or monomers are attached to the 3’ or the 5’ end of the
oligonucleotide of the invention. In a more preferred embodiment, 4 abasic sites or
monomers are ed at the 3’ terminus of the (NAG)m oligonucleotide according to the
invention. Even more preferably, 4 abasic sites or monomers are attached at the 3’
terminus of the (NAG)7 oligonucleotide of the invention. In a most preferred embodiment,
an oligonucleotide of the invention comprises 4 monomers of l-deoxyribose, 1,2-
dideoxyribose, and/or l-deoxyO-methylribose that are present at the 3’ us of said
oligonucleotide of the invention, preferably wherein said oligonucleotide of the invention
is (NAG)7.
The RNA binding cs and/or thermodynamic properties are at least in part determined
by the melting temperature of an oligonucleotide of the invention (Tm, calculated with the
oligonucleotide properties calculator (http://www.unc.edu,’~cail/biotooE/oligo/indexhtml)
for single stranded RNA using the basic Tm and the nearest neighbour model, of the
oligonucleotide according to the invention bound to its target RNA (using RNA structure
n 4.5).
Immunogenicity may be assessed in an animal model by ing the presence of CD4+
and/or CD8+ cells and/or atory mononucleocyte infiltration in muscle biopsy of
said animal. Immunogenicity and/or toxicity may also be assessed in blood of an animal or
of a human being treated with a compound or an oligonucleotide of the invention or an
ucleotide part of said compound by detecting the presence of an antibody
recognizing said compound or oligonucleotide of the invention or an oligonucleotide part
of said nd using a standard immunoassay known to the skilled person.
Toxicity may be assessed in blood of an animal or a human being treated with a compound
or an oligonucleotide of the invention or an oligonucleotide part of said compound by
detecting the presence of a cytokine and/or by detecting complement activation. In this
context, a cytokine may be IL-6, TNF-oc, IFN-oc and/or IP-lO. The presence of each of
these cytokines may be assessed using ELISA, preferably ch ELISA. The ELISA kit
from R&D Systems may be used to assess the presence of human IL-6, TNF-oc, IL-10, or
from Verikine for , or from Invitrogen for monkey IL-6 and TNF-oc. Complement
tion may be assessed by ELISA by assessing the presence of Bb and C3a. A suitable
ELISA to this end is from Quidel (CA, San Diego).
An increase in immunogenicity preferably corresponds to a detectable increase of at least
one of these cell types by comparison to the amount of each cell type in a corresponding
muscle biopsy of an animal before treatment or treated with a compound or an
oligonucleotide of the invention or an oligonucleotide part of said compound having no
modified bases. Alternatively, an se in genicity may be assessed by detecting
the presence or an increasing amount of an antibody recognizing said compound or
oligonucleotide of the invention or an oligonucleotide part of said compound using a
standard immunoassay.
A decrease in immunogenicity preferably corresponds to a detectable decrease of at least
one of these cell types by comparison to the amount of corresponding cell type in a
corresponding muscle biopsy of an animal before treatment or treated with a corresponding
compound or oligonucleotide of the invention or an oligonucleotide part of said compound
having no d base. Alternatively a se in genicity may be assessed by
the absence of or a decreasing amount of said compound or oligonucleotide of the
invention or an oligonucleotide part of said compound and/or neutralizing antibodies using
a standard immunoassay.
An increase in toxicity preferably corresponds to a detectable increase of a cytokine as
identified above and/or to a detectable increase of complement activation by comparison to
the situation of an animal before treatment or treated with a compound or ucleotide
ofthe invention or an oligonucleotide part of said compound having no modified bases.
A decrease in toxicity preferably corresponds to a able decrease of a cytokine as
identified above and/or to a detectable decrease of the complement activation of an animal
before treatment or treated with a corresponding compound or oligonucleotide of the
invention or an oligonucleotide part of said compound having no modified base.
A ne modification includes a modified version of the odiester present in
RNA. In this respect, the term “backbone” is to be interpreted as the internucleoside
linkage. Examples of such backbone modifications are phosphorothioate (PS), chirally
pure orothioate, phosphorodithioate (P82), phosphonoacetate (PACE),
onoacetamide (PACA), thiophosphonoacetate, osphonoacetamide,
phosphorothioate prodrug, H-phosphonate, methyl phosphonate, methyl onothioate,
methyl phosphate, methyl phosphorothioate, ethyl phosphate, ethyl phosphorothioate,
boranophosphate, boranophosphorothioate, methyl boranophosphate, methyl
boranophosphorothioate, methyl boranophosphonate, methyl boranophosphonothioate, and
their derivatives. Other possible modifications include phosphoramidite, phosphoramidate,
N3’9P5’ oramidate, phosphordiamidate, phosphorothiodiamidate, sulfamate,
dimethylenesulfoxide, sulfonate, thioacetamido nucleic acid (TANA), and their
derivatives. An oligonucleotide ing to the invention may comprise l, 2, 3, 4, 5, 6, 7,
8, 9, 10 or more backbone modifications. It is also encompassed by the invention to
introduce more than one distinct backbone modification in said oligonucleotide of the
invention.
In a preferred embodiment, an oligonucleotide according to the invention comprises at
least one phosphorothioate ation. In a more preferred embodiment, an
oligonucleotide of the ion is fully phosphorothioate modified.
Other chemical modifications of an oligonucleotide according to the ion include
peptide nucleic acid (PNA), boron-cluster modified PNA, pyrrolidine-based oxy-peptide
nucleic acid ), glycol- or glycerol-based nucleic acid (GNA), threose-based
nucleic acid (TNA), acyclic threoninol-based nucleic acid (aTNA), morpholino-based
oligonucleotide (PMO, PMO-X), cationic morpholino-based oligomers (PMOPlus),
oligonucleotides with integrated bases and backbones (ONIBs), pyrrolidine-amide
ucleotides (POMs), and their derivatives. In a preferred embodiment, the
oligonucleotide according to the invention is modified with morpholino-based nucleotides
(PMO) or peptide nucleotides (PNA) over its entire length.
With the advent of nucleic acid mimicking logy it has become possible to generate
les that have a similar, preferably the same isation characteristics in kind not
necessarily in amount as nucleic acid . Such functional equivalents are of course also
suitable for use in the invention.
The skilled person will understand that not each sugar, base, and/or backbone may be
modified the same way. Several distinct sugar, base and/or backbone modifications may be
combined into one single ucleotide ing to the invention.
A person skilled in the art will also recognize that there are many synthetic derivatives of
ucleotides. Therefore, “oligonucleotide” es, but is not d to
phosphodiesters, phosphotriesters, phosphorothioates, phosphodithioates,
phosphorothiodiamidate and H-phosphonate derivatives. It encompasses also both
naturally occurring and synthetic oligonucleotide derivatives.
Preferably, said oligonucleotide according to the invention comprises RNA, as RNA/RNA
duplexes are very stable. It is preferred that an RNA oligonucleotide ses a
modification providing the RNA with an additional property, for instance resistance to
endonucleases, exonucleases, and RNaseH, additional hybridisation strength, increased
stability (for instance in a bodily fluid), increased or decreased flexibility, reduced toxicity,
increased intracellular transport, tissue-specif1city, etc. Preferred modifications have been
identified above.
Preferably, said oligonucleotide according to the invention comprises or consists of 2’-O-
methyl RNA monomers connected through a phosphorothioate backbone. Such an
oligonucleotide consisting of 2’-O-methyl RNA monomers and a phosphorothioate
backbone can also be referred to as “2’-O-methyl phosphorothioate RNA”. Also, when
only a portion of the ucleotide ing to the invention consists of 2’-O-methyl
RNA rs and a phosphorothioate backbone, this portion can be referred to as “2’-O-
methyl orothioate RNA”. The oligonucleotide according to the invention then
comprises 2’-O-methyl RNA monomers connected through a phosphorothioate backbone
or 2’-O-methyl phosphorothioate RNA. One embodiment thus provides an oligonucleotide
according to the invention which comprises RNA further containing a modification,
preferably a 2’-O-methyl modif1ed ribose (RNA), more ably a ethyl
phosphorothioate RNA.
Hybrids n one or more of the equivalents among each other and/or together with
c acid are of course also le.
Oligonucleotide according to the invention containing at least in part naturally occurring
DNA nucleotides are useful for inducing degradation of DNA-RNA hybrid molecules in
the cell by RNase H activity (EC.3.l.26.4).
Naturally occurring RNA ribonucleotides or ke synthetic ribonucleotides
sing oligonucleotides according to the invention are encompassed herein to form
double stranded RNA-RNA hybrids that act as enzyme-dependent antisense through the
RNA interference or ing (RNAi/siRNA) pathways, involving target RNA recognition
through sense-antisense strand g followed by target RNA degradation by the RNA-
induced silencing complex (RISC).
Alternatively or in addition, the oligonucleotide according to the invention can interfere
with the processing or expression of sor RNA or messenger RNA c blocking,
RNase-H ndent processes) in particular but not limited to RNA splicing and exon
skipping, by binding to a target sequence of RNA transcript and getting in the way of
processes such as ation or blocking of splice donor or splice acceptor sites.
Moreover, the oligonucleotide according to the invention may inhibit the binding of
proteins, nuclear factors and others by steric hindrance and/or ere with the authentic
spatial folding of the target RNA and/or bind itself to proteins that originally bind to the
target RNA and/or have other effects on the target RNA, thereby buting to the
destabilization of the target RNA, preferably mRNA, and/or to the se in amount of
diseased or toxic transcript thereby leading to a decrease of nuclear accumulation of
ribonuclear foci in diseases like DMl as identified later .
As herein defined, an oligonucleotide according to the invention may comprise nucleotides
with (RNaseH resistent) al substitutions at at least one of its 5’or 3’ ends, to provide
intracellular stability, and comprises less than 9, more preferably less than 6 consecutive
(RNaseH-sensitive) deoxyribose nucleotides in the rest of its sequence. The rest of the
ce is preferably the center of the sequence. Such ucleotide is called a gapmer.
Gapmers have been extensively described in . Gapmers are designed to
enable the recruitment and/or activation of RNaseH. Without wishing to be bound by
theory, it is believed that RNaseH is recruited and/or activated via binding to the central
region of the gapmer made of deoxyriboses. The oligonucleotide according to the
invention which is preferably substantially independent of RNaseH is designed in order to
have a central region which is substantially not able to recruit and/or activate RNaseH. In a
preferred ment, the rest of the ce of the oligonucleotide of the invention,
more preferably its central part comprises less than 9, 8, 7, 6, 5, 4, 3, 2, l, or no
deoxyribose. Accordingly this oligonucleotide according to the invention is preferably
partly till fully substituted as earlier defined herein. Partly substituted preferably means
that the oligonucleotide according to the invention comprises at least 50% of its
nucleotides that have been substituted, at least 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, or 100% (i.e. fully) substituted.
As indicated above, the oligonucleotide according to the invention as represented by H—
NAG)m—(Y)q—H preferably does not comprise e as nucleotide or hypoxanthine
as nucleobase.
On the other hand, when the oligonucleotide according to the invention is part of a
conjugate with a peptide part, said oligonucleotide part preferably contains or comprises an
inosine and/or a nucleotide containing a base able to form a Wobble base pair. More
preferably said oligonucleotide part comprises an inosine. In the current invention, a
compound comprising an oligonucleotide part comprising at least one e is attractive.
In an especially preferred embodiment, in (NAG)m all or almost all occurrences of A are
replaced by inosine (I). When all occurrences of A are replaced by I, the ucleotide
according to the invention comprises m occurrences of 1. “Almost all occurrence of A
replaced by I” is to be understood as that m — l, 2 or 3 occurrences of A are replaced by 1.
Such compound can be used to treat at least two diseases, myotonic dystrophy l which is
caused by a (CUG)n expanded repeat, and e. g. gton’s e, which is caused by a
(CAG)n expanded repeat. Specifically targeting these expansion repeats would otherwise
e two compounds, each compound comprising one distinct oligonucleotide part. An
oligonucleotide part comprising an inosine and/or a tide containing a base able to
form a wobble base pair may be defined as an ucleotide wherein at least one
tide has been substituted with an inosine and/or a nucleotide containing a base able
to form a Wobble base pair. The d person knows how to test whether a nucleotide
contains a base able to form a Wobble base pair. Since for example inosine can form a base
pair with uracil, adenine, and/or cytosine, it means that at least one tide able to form
a base pair with , adenine and/or cytosine has been substituted with inosine.
However, in order to safeguard specif1city, the inosine containing oligonucleotide
preferably comprises the substitution of at least one nucleotide able to form a base pair
with uracil or adenine or cytosine. More preferably, all nucleotides able to form a base pair
with uracil or adenine or cytosine are substituted with inosine. An oligonucleotide part
complementary to a repeat sequence (CUG)n will preferably comprise or consist of (NIG)n
in which N is C or 5-methylcytosine. It is also to be encompassed by the present invention
that since at least one nucleotide has been substituted by inosine and/or a tide
containing a base able to form a Wobble base pair in an oligonucleotide part as defined
herein, that an oligonucleotide part complementary to a repeat sequence such as (CUG)n
may comprise or consist of (NIG)n in which N is C or 5-methylcytosine. If one takes
(NIG)n in which N is C or 5-methylcytosine as example, having 11 as 3 as example, the
ion encompasses any possible oligonucleotide part based on a given formula such as
(NIG)3 comprising 1 or 2 or 3 inosine(s) at the indicated position: (NAG)(NIG)(NAG),
(NIG)(NAG)(NAG), (NIG)(NAG)(NIG), (NIG)(NIG)(NAG), (NIG)(NIG)(NIG) (in which
N is C or 5-methylcytosine). It is to be understood that the (NAG)m part of the
oligonucleotide part of the compound of the invention may comprise of consists of (NIG)n.
In this respect, n is an r which is equal to or smaller than m. In a preferred
embodiment, n is equal to m, and thus in the compound of the invention, (NAG)m part of
the oligonucleotide part consists of (NIG)m. In this embodiment, at least one of adenine
nucleobases contains a base modification, in particular a hypoxanthine nucleobase.
Preferably, the (NAG)m part of the oligonucleotide part of the compound of the invention
comprises 1, 2, 3, 4, 5, m hypoxanthine nucleobases.
...,
Thus, in a preferred ment the oligonucleotide ing to the invention comprises:
(a) at least one base modification selected from 2-thiouracil, 2-thiothymine, 5-
2O methylcytosine, 5-methyluracil, e, 2,6-diaminopurine, and/or
(b) at least one sugar modification selected from ethyl, 2’-O-(2-
methoxy)ethyl, morpholino, a bridged nucleotide or BNA, or the oligonucleotide
comprises both bridged nucleotides and 2’-deoxy d nucleotides
(BNA/DNA mixmers or gapmers), or both 2’-O-(2-methoxy)ethyl tides and
DNA nucleotides (2’-O-(2-methoxy)ethyl/DNA mixmers or s), and/or
(c) at least one backbone modification selected from phosphorothioate and
phosphordiamidate.
In another preferred embodiment, the oligonucleotide according to the invention is
d over its entire length with one or more of the same modification, selected from
(a) one of the base modifications, and/or (b) one of the sugar modifications, and/or (c) one
ofthe backbone modifications.
In a preferred embodiment, the oligonucleotide or the oligonucleotide part of the
compound according to the invention comprises at least one modification selected from the
group consisting of ethyl phosphorothioate, lino orodiamidate,
locked nucleic acid and peptide nucleic acid. In a more preferred embodiment, the
oligonucleotide or oligonucleotide part of the compound according to the invention
comprises one or more 2’-O-methyl phosphorothioate rs. In a more preferred
embodiment, the oligonucleotide or oligonucleotide part of the compound according to the
invention consists of 2’-O-methyl phosphorothioate monomers. In other words, it is
preferred that the oligonucleotide part of the compound according to the invention is a 2’-
O-methyl phosphorothioate oligonucleotide. In a preferred embodiment, the
oligonucleotide or oligonucleotide part of the compound ing to the invention
comprises at least one base selected from 2,6-diaminopurine, 2-thiouracil, 2-thiothymine,
-methyluracil, thymine, 8-azadeazaguanosine, and/or hypoxanthine.
Linkingpart ofthe conjugate represented by LGAQSNF/(NA G)”,
In order to prepare the compound according to the first aspect of the present invention,
which can be represented by LGAQSNF/(NAG)m, coupling of the oligonucleotide part to
the e or peptidomimetic part according to this aspect of the present invention occurs
via known s to couple compounds to amino acids or peptides. A common method is
to link a moiety to a free amino group or free hydroxyl group or free carboxylic acid group
or free thiol group in a peptide or peptidomimetic. Common conjugation methods include
thiol/maleimide coupling, amide or ester or thioether bond formation, or heterogeneous
disulf1de ion. The skilled person is well aware of standard try that can be
used to bring about the required ng. The oligonucleotide part may be coupled
directly to the peptide part or may be coupled via a spacer or linker molecule. Such a
spacer or linker may be divalent, thus linking one peptide or peptidomimetic part with one
ucleotide part, or multivalent. Multivalent spacers or s may be used to link
more than one peptide or peptidomimetic part with one oligonucleotide part. Divalent and
multivalent linkers or spacers are known to the skilled person. It is not necessary that the
oligonucleotide part is covalently linked to the peptide or peptidomimetic part according to
this aspect of the invention. It may also be associated or conjugated via ostatic
interactions. Such a valent linkage is also subject of the present invention, and is to
be understood as encompassed in the terms “link” and “linkage”. In one embodiment the
present invention also s to a compound comprising a peptide or peptidomimetic part
according to this aspect of the invention and a linking part, for linking the peptide part to
the oligonucleotide part. The linking part may not be a peptide or may be a peptide. The
linking part for example may be a (poly)cationic group that complexes with a biologically
active poly- or oligonucleotide. Such a (poly)cationic group may be a linear or branched
version of spermine or polyethyleneimine, poly-ornithine, poly-lysine, poly-arginine and
the like. The linking part may also be neutral as for example a g part comprising or
consisting of polyethylene .
The peptide or peptidomimetic part of a compound ing the first aspect of the
invention can be linked, coupled or conjugated to the ucleotide part via the C-
us, via the N—terminus or via a side chain of an amino acid, and could be linked to
the 5’-terminal nucleotide, the 3’-terminal nucleotide or a non-terminal nucleotide through
the base, backbone or sugar moiety of that particular nucleotide of the oligonucleotide part.
Any possible known way of coupling or linking an oligonucleotide part to a peptide part
may be used in this aspect of the present invention to obtain a compound according to this
aspect of the invention. A peptide part may be coupled or linked to an oligonucleotide part
through a linkage including, but not limited to, linkers comprising a thioether, amide,
2O amine, oxime, disulf1de, thiazolidine, urea, thiourea, ester, thioester, carbamate,
thiocarbamate, carbonate, thiocarbonate, hydrazone, sulphate, sulphamidate, phosphate,
phosphorothioate, or lic-oxime moiety, or a linkage obtained via Diels-Alder
cycloaddition, Staudinger ligation, native ligation or Huisgen l,3-dipolar cycloaddition or
the copper catalyzed variant thereof. In a preferred ment, the linkage comprises a
thioether moiety. In one ment, the invention provides a compound comprising a
e part comprising LGAQSNF and an oligonucleotide part comprising (NAG)m in
which N is 5-methylcytosine, wherein said compound is represented by formula A.
P E 0 fi
'I' R1—X \/\N
N—R3
OLIGONUCLEOTIDE
D Y—R4—O—lT—O
o 0
E o
Inwhich
o O
FL'V-LJKK’If MAME/i or Elk/fiorabsent
R1 is NHRZ NHR2
R2 is acetyl or H,
R3 is substituted or unsubstituted (C1-C10)alkyl, (C1-C10)cycloalkyl, aryl or (C1-C10)aralkyl,
R4 is (C1-C15)alkyl, ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene
lO glycol, polyethylene glycol or derivative,
X is S, C=O or NH,
Y is S or NH,
Z is S or O,
r and s are 0 or 1, provided that r + s = O or 1,
wherein R1 is connected via an amide or ester bond with an amine or alcohol at the N-
us, inus or a side chain of an amino acid of the peptide part,
n R4 is connected to the 5’ or 3’ of the ucleotide part.
Preferably, X = S or NH when r = l.
In a preferred embodiment, this aspect of the invention provides a compound represented
by any of the formulae I-VII
WO 44906
ITIU——|'U|T|'U || 0
R1—X C\/\N _<lOIM83’|C?Q—‘IUZCOO| OCG)0 ZC O l— ITIO:I U ITI
Z 50 00
O O
r s
COMPOUND R1 R2 R3 X Y 1‘ S
I absent - - NH S l 0
II absent - - C=O I\H O 0
III 0 acetyl - C=O I\H O O
NH R2
IV 0 H ethyl S NH O 1
NH R2
V O H cyclohexyl S NH O 1
NH R2
VI 0 - cyclohexyl S NH O l
Elk/Hr:
VII 0 - cyclohexyl S NH O l
Elk/Hr:
VIII 0 acetyl ethyl S NH O 1
NH R2
In the nd according to formula I, X is the N-terminal amino group of the peptide
part; in the compound according to formula II, X is the C-terminal yl group of the
peptide part; in any of the compounds according to the formulae III-VIII, R1 is connected
to the N-terminus of the peptide part via an amide bond. In compounds V, VI and VII,
“cyclohexyl” is understood to be “cyclohexane-l,4-diyl” or “ l,4-cyclohexanediyl”.
The conjugation represented in formula I is well-known to the skilled person and is
preferably synthesized as explained in the examples. se, other methods of
WO 44906
conjugation are known in the art or will be known in the art. The peptide part could be
linked to the oligonucleotide part from the N—terminus, inus or a side chain of an
amino acid; and could be linked from the 5’-terminal nucleotide. The skilled person
understands that the peptide part may also be linked to the minal nucleotide or a non-
terrninal monomer through the base, backbone or sugar moiety of that particular monomer.
Equally preferred compounds according to this aspect of the invention are identical to
compounds I — VIII, except that the oligonucleotide is attached via its 3’-terminus to the
linking part.
In case an abasic site or monomer is present or attached to a terminus of the
oligonucleotide part of the compound of the invention, the peptide part is attached not to
the same terminus. Thus, in case a peptide part is coupled to the 5’ terminus of the
oligonucleotide part, then - if incorporated - the abasic site or monomer is attached to the
3’ us of the oligonucleotide part.
Peptide part of the conjugate represented by LGAQSNF/(NA G)”,
As already indicated above, the peptide part of the nd according to this aspect of
the invention comprises or ts of LGAQSNF. A peptide part in the context of this
aspect of the invention ses at least 7 amino acids. A compound according to this
2O aspect of the invention may comprise more than one peptide part as identified herein: a
compound according to this aspect of the invention may comprise l, 2, 3, 4, 5 ,6, 7, 8
peptide parts linked to an ucleotide part, all as identified herein. The peptide can be
fully constructed of naturally occurring o acids, or can contain one or more
modifications to backbone and/or side chain(s) with respect to L-amino acids. These
ations can be introduced by incorporation of amino acid mimetics that show
similarity to the natural amino acid. The group of peptides described above comprising one
or more mimetics of amino acids is referred to as peptidomimetics. In the context of this
aspect of the invention, mimetics of amino acids include, but are not limited to, [32- and [33-
amino acids, BZ’Z- [323, and [33’3-disubstituted amino acids, 0t,0t-disubstituted amino acids,
statine tives of amino acids, D-amino acids, d-hydroxyacids, d-aminonitriles, N-
alkylamino acids and the like. Additionally, amino acids in the peptide part of this aspect
WO 44906
of the invention may be glycosylated with one or more carbohydrate moieties and/or
tives, or may be phosphorylated.
In on, the C-terminus of the peptide might be carboxylic acid or carboxamide, or
other resulting from incorporation of one of the above mentioned amino acid mimetics.
rmore, the peptide part described above may contain one or more replacements of
native peptide bonds with groups including, but not limited to, sulfonamide, retroamide,
aminooxy-containing bond, ester, alkylketone, 0t,0t-difluoroketone, d-fluoroketone, peptoid
bond (N—alkylated glycyl amide bond). Furthermore, the peptide part mentioned above may
contain substitutions in the amino acid side chain (referring to the side chain of the
corresponding natural amino acid), for instance ophenylalanine, 4-hydroxylysine, 3-
roline, 2-nitrotyrosine, N—alkylhistidine or B-branched amino acids or B-branched
amino acid mimetics with chirality at the B-side chain carbon atom opposed to the natural
chirality (e.g. hreonine, allo-isoleucine and derivatives). In one other embodiment,
above mentioned peptide may contain close structural analogues of amino acid or amino
acids mimetics, for instance ornithine instead of lysine, homophenylalanine or
phenylglycine instead of phenylalanine, ine instead of e, pyroglutamic acid
instead of glutamic acid, cine instead of e or the sulfur-oxidized versions of
methionine and/or cysteine. The linear and cyclized forms of the peptide part mentioned
above are covered by this patent, as well as their retro, inverso and/or retroinverso
2O analogues. To those skilled in the art many more close ions may be known, but the
fact that these are not mentioned here does not limit the scope of the present invention. In
one embodiment, a peptide part or peptidomimetic part according to this aspect of the
present invention is at most 30 amino acids in length, or at least 25 amino acids or 20
amino acids or 19, 18, l7, 16, 15, l4, l3, 12, ll, 10, 9, 8 or 7 amino acids in length. A
preferred peptide part comprises or consists of LGAQSNF and at least 0, l, 2, 3 or more
amino acids at the N—terminus and/or at the C-terminus: for example
XXXLGAQSNFXXX, wherein X may be any amino acid.
Application
A compound or oligonucleotide of the ion is particularly useful for treating, delaying
and/or preventing and/or treating and/or curing and/or ameliorating a human genetic
disorder as myotonic dystrophy type 1, spino-cerebellar ataXia 8 and/or Huntington’s
disease-like 2 caused by repeat expansions in the transcripts of DMl/DMPK, SCA8 or
JPH3 genes respectively. Preferably, these genes are from human origin. A preferred
genomic DNA sequence of a human DMPK, respectively SCA8, JPH3 gene is represented
by SEQ ID NO: 10, 11, 12. A corresponding preferred coding cDNA sequence of a human
DMPK, respectively SCA8, JPH3 gene is represented by SEQ ID NO: 13, 14, 15.
In a preferred embodiment, in the context of the invention, a compound or oligonucleotide
as designed herein is able to delay and/or cure and/or treat and/or prevent and/or ameliorate
a human genetic disorder as myotonic dystrophy type 1, spino-cerebellar ataxia 8 and/or
Huntington’s e-like 2 caused by CUG repeat expansions in the transcript of the
DMl/DMPK, SCA8 or JPH3 genes when this compound or oligonucleotide is able to
reduce or decrease the number of CUG repeats in the transcript of a diseased allele of a
DMl/DMPK, SCA8 or JPH3 gene in a cell of a patient, in a tissue of a patient and/or in a
patient.
Although in the majority of ts, a “pure” CUG repeat is t in a transcribed gene
sequence in the genome of said patient. However, it is also assed by the invention,
that in some patients, said repeat is not qualified as “pure” or is qualified as a “variant”
when for e said repeat is interspersed with at least 1, 2, or 3 nucleotide(s) that do
not fit the nucleotide(s) of said repeat a C., et al,).
An oligonucleotide according to the invention may not be 100% reverse complementary to
a targeted CUG repeat. Usually an oligonucleotide of the invention may be at least 90%,
95%, 97%, 99% or 100% reverse complementary to a CUG repeat.
In the case of DM1, a CUG repeat is present in exon 15 of the DMPK transcript. A CUG
repeat may be herein defined as a consecutive repetition of at least 30, 35, 38, 39, 40, 45,
50, 55, 60, 70, 100, 200, 500 of the repetitive unit CUG or more comprising a trinucleotide
repetitive unit CUG, in a transcribed gene sequence of the DMPK gene in the genome of a
t, including a human subject.
In the case of cerebellar ataxia 8, the repeat expansion is located in the 3 ’UTR of the
SCA8 gene. The SCA8 locus is bidirectionally transcribed and produces RNAs with either
(CUG)n or (CAG)n expansions. (CAG)n expansion ripts produce a nearly pure
polyglutamine (polyQ) protein. A CUG or a CAG repeat may be herein defined as a
consecutive repetition of at least 65, 70, 75 500 of the repetitive unit CUG
, 80, 100, 200,
or more comprising a CUG trinucleotide repetitive unit respectively of the repetitive unit
CAG comprising a CAG trinucleotide repetitive unit, in a transcribed gene sequence of the
SCA8 gene in the genome of a subject, including a human subject.
Huntington’s disease-like 2 is caused by a (CUG)n expansion in the transcript of the JPH3
gene. Depending on the alternative ng of the JPH3 transcript, the CUG repeat could
lie in an intron, in the 3’ UTR or in a coding region encoding a polyleucine or polyalanine
tract. A CUG repeat may be herein defined as a utive tion of at least 35, 40,
41, 45, 50, 50, 55, 60 or more, of the repetitive unit CUG sing a leotide
repetitive unit CUG, in a transcribed gene sequence of the JPH3 gene in the genome of a
subject, including a human subject.
Throughout the invention, the term CUG repeat may be replaced by (CUG)n wherein n is
an integer that may be 10, 20, 30 or not higher than 30 when the repeat is present in exon
of the DMPK transcript of a healthy individual, 20, 30, 40, 50, 60, 65 or not higher
than 65 when the repeat is present in the SCA8 gene of a healthy individual or 10, 20, 30,
or not higher than 35 when the repeat is present in the JPH3 gene of a healthy
individual. In the case of DM1, spino-cerebellar ataxia 8 or Huntington’s patients, 11 may
have other value as indicated above.
It preferably means that the compound or oligonucleotide of the invention reduces the
detectable amount of e-associated or disease-causing or mutant transcript containing
an extending or unstable number of CUG repeats in a cell of said patient, in a tissue of said
patient and/or in a t. Alternatively or in combination with previous ce, said
compound may reduce the translation of said mutant ript. The reduction or decrease
ofthe number of CUG repeats or of the quantity of said mutant transcript may be of at least
1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, 100% by comparison to the number of CUG repeats or of the
ty of said mutant transcript before the treatment. The reduction may be assessed by
Northern Blotting or Q-RT-PCR, preferably as carried out in the experimental part. A
compound or oligonucleotide of the invention may first be tested in the cellular system as
used in the experimental comprising a 500 CUG repeat.
Alternatively or in combination with previous preferred embodiment, in the context of the
invention, a compound or an oligonucleotide of the ion as designed herein is able to
delay and/or cure and/or treat and/or prevent and/or ameliorate a human genetic er as
myotonic dystrophy type 1, spino-cerebellar ataxia 8 and/or Huntington’s disease-like 2
caused by a CUG repeat expansion in the transcript of the DMl/DMPK, SCA8 or JPH3
genes when this compound or oligonucleotide is able to alleviate one or more symptom(s)
and/or characteristic(s) and/or to improve a parameter linked with or ated with
myotonic dystrophy type 1, spino-cerebellar ataxia 8 and/or gton’s disease-like 2 in
an individual. A compound or oligonucleotide as defined herein is able to improve one
parameter or reduce a symptom or teristic if after at least one week, one month, six
month, one year or more of treatment using a dose of the compound or oligonucleotide of
the invention as identified herein said parameter is said to have been improved or said
m or characteristic is said to have been reduced.
ement in this context may mean that said parameter had been significantly changed
towards a value of said parameter for a healthy person and/or towards a value of said
parameter that corresponds to the value of said parameter in the same individual at the
onset of the treatment.
ion or alleviation in this t may mean that said symptom or characteristic had
been significantly changed towards the absence of said symptom or characteristic which is
2O characteristic for a healthy person and/or towards a change of said symptom or
characteristic that corresponds to the state of the same individual at the onset of the
treatment.
In this context, a preferred symptom for myotonic dystrophy type 1 is myotonia, muscle
th or stumbles and falls. Each of these symptoms may be assessed by the physician
using known and described methods.
Myotonia could be assessed using an EMG (ElectroMyoGram): an EMG is a quantitative
test of handgrip strength, ia, and/or fatigue in myotonic dystrophy, (Tones C. et al,)
as known to the skilled person. If there is a detectable reduction in myotonia as assessed by
EMG towards an EMG pattern of a healthy person, ably after at least one week, one
month, six month, one year or more of treatment using a dose of the compound of the
invention as identified herein, we preferably conclude that said myotonia has been d
or alleviated.
Other preferred symptoms of myotonic dystrophy type 1 are muscle strength (Hebert et
al.) or a reduction in stumbles and falls (Wiles, et al,). Here also, If there is a detectable
improvement of muscle strength or detectable reduction of es and falls s
muscle strength or stumbles and falls of a healthy person, preferably after at least one
week, one month, six month, one year or more of treatment using a dose of the compound
or an oligonucleotide of the ion as identified herein, we preferably conclude that said
muscle strength has been improved or that said stumbles and falls has been reduced or
alleviated.
In this context, a preferred symptom for spino-cerebrellar ataxia 8 includes ataxia,
proprioceptive and nation defects including gait impairment and a general lack of
motor control, including upper motor neuron dysfunction, dysphagia, peripheral sensory
disturbances. Each of these symptoms may be assessed by the physician using known and
described s: ataxia may be assessed by the physician using known and described
s: such as static posturography or dynamic posturography. Static posturography
essentially measures various aspects of balance and sway. While little is documented on
the use of techniques for diagnosing the presence of a symptom ated with SCA8, we
assumed that techniques used for diagnosing the same symptom in other closely related
indications as SCA6 could be used for diagnosing SCA8 (Nakamura et al, Januario et al,).
For example the ICARS (International Cooperative Ataxia Rating Score) may be used for
diagnosing SCA8 (assessed in Nakamura et al, or Trouillas P. et al,). As another e,
the OASI (Overall Stability Index) may be used for diagnosing SCA8 (assessed in Januario
et al,).
For more d motor function skills, common hand on tests such as the Jebson
timed test the Perdue Pegboard test or 9 peg hole test may be ered, although again,
not specific to, or validated in, this indication. If there is a detectable reduction in at least
one of these symptoms of cerebrellar ataxia 8 or a detectable change of the ICARS
and/or OASI assessed as described above towards the value of said symptom or of said
ICARS or OASI of a healthy , preferably after at least one week, one month, six
month, one year or more of treatment using a dose of the compound or oligonucleotide of
the invention as identified herein, we preferably conclude that said symptom or said
ICARS or OASI has been reduced or alleviated or changed using a compound of the
invention.
In this context, a preferred symptom for Huntington’s disease-like 2 includes chorea and/or
dystonia chorea and/or dystonia. Each of these symptoms may be assessed by the physician
using known and bed methods. They may be diagnosed by genetic testing (Walker,et
al ) and by clinical assessment with the use of scales such as the Unified Huntington’s
Disease Rating Scale Movement Disorders Vol. II No. 2, 1996, pp. 2, and Mahant
et al,). If there is a detectable reduction in at least one of these symptoms of Huntington’s
e-like 2 assessed as bed above towards the value of said symptom of a healthy
person, preferably after at least one week, one month, six month, one year or more of
ent using a dose of the compound or oligonucleotide of the invention as identified
herein, we preferably conclude that said symptom has been reduced or alleviated using a
compound or ucleotide of the invention.
A parameter for myotonic phy type 1 may be the splicing pattern of certain
transcripts (for example ClC-l, SERCA, IR, Tnnt, Tau). Myotonic dystrophy is
characterized by an embryonic splicing pattern for a wide variety of transcripts (Aberrant
alternative splicing and extracellular matrix gene expression in mouse models of myotonic
2O dystrophy, Hongquing D. et al ). A splicing pattern of these genes could be visualised
using PCR or by using c screens. When the nic ng pattern of at least
one of the genes identified above had been found altered towards wild type splicing pattern
of the corresponding gene after at least one month, six month or more of treatment with a
dose of a compound or an oligonucleotide of the ion as identified herein, one could
say that a compound or an oligonucleotide of the ion is able to improve a parameter
linked with or associated with myotonic dystrophy type 1 in an individual.
Another parameter for myotonic dystrophy type 1 may be insulin resistance (measured by
blood glucose and HbAlc levels), the normal ranges of which are 3.6 — 5.8mmol/L and 3-
8mmol/L respectively. Reduction of these values towards or within the normal range
would indicate a positive benefit. When at least one of these values had been found altered
towards wild type values after at least one month, six month or more of treatment with a
dose of a compound or oligonucleotide of the invention as identified herein, one could say
that a nd or oligonucleotide of the invention is able to improve a parameter linked
with or associated with myotonic dystrophy type 1 in an individual.
Another parameter for myotonic dystrophy type 1 is the number of RNA-1Vfl3NL (muscle
blind protein) foci or nuclear inclusions in the nucleus which could be ized using
fluorescence in situ hybridization (FISH). DMl ts have 5 to 20 RNA-1Vfl3NL foci in
their nucleus (Taneja KL et al,). A r inclusion or foci may be defined as an
aggregate or an abnormal structure t in the s of a cell of a DMl patient and
which is not t in the nucleus of a cell of a healthy person. When the number of foci
or r inclusions in the nucleus is found to have changed (analyzed with FISH) and
preferably to be decreased by comparison to the number of nuclear foci or nuclear
inclusions at the onset of the treatment, one could say that a compound or an
oligonucleotide of the invention is able to improve a parameter linked with or associated
with myotonic phy in an individual. The decrease of the number of foci or nuclear
inclusions may be of at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by comparison to the number of
foci or nuclear inclusions at the onset of the treatment. Preferably, the muscle blind protein
1Vfl3NL is detached from these foci or nuclear inclusions (as may be analyzed with
immunofluorescence microscopy) and more preferably free available in the cell. The
decrease of the number of RNA-1Vfl3NL may be of at least 1%, 5%, 10%, 15%, 20%, 25%,
%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by
comparison to the number of RNA-1Vfl3NL at the onset of the treatment. A free available
1Vfl3NL in the cell may be detected using immunofluorescence microscopy: a more diffuse
staining of 1Vfl3NL will be seen and less to no co-localization with nuclear (CUG)n foci or
nuclear ions anymore.
A parameter for spino-cerebellar ataxia 8 includes a decrease or a lowering of the amount
of polyglutamine protein (preferably assessed by Western blotting) and/or a decrease or a
lowering of the number of nuclear polyglutamine inclusions (preferably assessed by
immunofluorescence microscopy). Beside the (CAG)n transcripts that form polyglutamine
protein inclusions, (CUG)n transcripts form r inclusions or foci could bevisualized
using FISH. The presence of a polyglutamine protein and nuclear inclusion is preferably
assessed in s. A nuclear inclusion or foci may be defined as an aggregate or an
abnormal structure present in the nucleus of a cell of a spino-cerebellar ataXia 8 patient and
which is not present in the nucleus of a cell of a y person. When the number of foci
or nuclear inclusions in the nucleus is found to have changed (analyzed with FISH) and
preferably to be decreased by comparison to the number of r foci or nuclear
inclusions at the onset of the treatment, one could say that a compound or an
oligonucleotide of the invention is able to improve a parameter linked with or associated
with spino-cerebellar ataxia 8 in an indiVidual. The decrease of the number of foci or
nuclear inclusions may be of at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by ison to
the number of foci or nuclear inclusions at the onset of the ent. A decrease of the
amount of quantity of a polyglutamine n may be of at least 1%, 5%, 10%, 15%,
%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 100% by comparison to the quantity of said protein detected at the onset of the
treatment. Another parameter would be the decrease in (CUG)n transcript or of the quantity
of said mutant transcript. This may be of at least. 1%, 5%, 10%, 15%, 20%, 25%, 30%,
%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by
comparison to the ty of said transcript detected at the onset of the treatment
A parameter for Huntington’s e-like 2 includes the decrease of or lowering the
pathogenic polyleucine or polyalanine tracts (Western blotting and immunofluorescence
microscopy). A decrease of the amount or of quantity of the polyleucine or anine
tract may be ofat least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by comparison to the quantity of said
tract assessed at the onset of the treatment. Another parameter would be the se in
(CUG)n transcript or of the quantity of said mutant transcript.. This may be of at least 1%,
%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 100% by comparison to the quantity of said transcript detected at the
onset of the treatment. Another parameter for Huntington’s disease-like 2 es the
number of RNA-1Vfl3NL (muscleblind protein) foci in the nucleus as for myotonic
dystrophy.
A compound or an oligonucleotide ing to the invention is suitable for direct
administration to a cell, tissue and/or organ in vivo of an dual affected by or at risk of
developing myotonic dystrophy type 1, spino-cerebellar ataXia 8 and/or Huntington’s
e-like 2, and may be stered directly in vivo, ex vivo or in vilro. An individual
or a subject or a patient is preferably a mammal, more preferably a human being. A tissue
or an organ in this context may be blood.
In a preferred embodiment, a concentration of a compound or an oligonucleotide is ranged
from 0.01 nM to 1 uM is used. More preferably, the concentration used is from 0.05 to 400
nM, or from 0.1 to 400 nM, or from 0.02 to 400 nM, or from 0.05 to 400 nM, even more
preferably from 1 to 200 nM. Preferred concentrations are from 0.01 nM to 1 uM. More
preferably, the concentration used is from 0.3 to 400 nM, even more preferably from 1 to
200 nM.
Dose ranges of a compound or an ucleotide according to the invention are preferably
designed on the basis of rising dose studies in clinical trials (in vivo use) for which rigorous
ol requirements eXist. A compound or an oligonucleotide as defined herein may be
used at a dose which is ranged from 0.01 to 500 mg/kg, or from 0.01 to 250 mg/kg or 0.01
to 200 mg/kg or 0.05 to 100 mg/kg or 0.1 to 50 mg/kg or 0.1 to 20 mg/kg, preferably from
0.5 to 10 mg/kg.
The ranges of concentration or dose of compound or oligonucleotide as given above are
preferred trations or doses for in vitro or ex vivo uses. The skilled person will
tand that depending on the identity of the compound or oligonucleotide used, the
target cell to be treated, the gene target and its sion levels, the medium used and the
transfection and tion conditions, the concentration or dose of compound or
oligonucleotide used may further vary and may need to be optimised any further.
More preferably, a compound or ucleotide used in the invention to prevent, treat or
delay myotonic dystrophy type 1, spino-cerebellar ataXia 8 and/or Huntington’s disease-
like 2 is synthetically produced and administered directly to a cell, a tissue, an organ and/or
a patient or an individual or a subject in a formulated form in a pharmaceutically
acceptable composition. Administration of a compound or oligonucleotide of the invention
may be local, topical, systemic and/or parenteral. The delivery of said pharmaceutical
composition to the subject is preferably carried out by one or more parenteral injections,
e.g. intravenous and/or subcutaneous and/or intramuscular and/or intrathecal and/or
2012/050273
intranasal and/or intraventricular and/or intraperitoneal, ocular, urogenital enteral,
intravitreal, intracerebral, intrathecal, epidural and/or oral administrations, preferably
injections, at one or at multiple sites in the human body. An intrathecal or intraventricular
administration (in the cerebrospinal fluid) is preferably realized by ucing a diffusion
pump into the body of a subject. Several diffusion pumps are known to the skilled person.
Pharmaceutical compositions that are to be used to target a compound or an
oligonucleotide as defined herein may comprise various excipients such as diluents, flllers,
vatives, solubilisers and the like, which may for instance be found in Remington et
al. The compound as described in the ion may possess at least one ionizable group.
An ionizable group may be a base or acid, and may be charged or neutral. An ionizable
group may be present as ion pair with an riate rion that s opposite
charge(s). Examples of cationic counterions are sodium, potassium, cesium, Tris, m,
calcium, magnesium, trialkylammonium, triethylammonium, and tetraalkylammonium.
Examples of anionic counterions are chloride, bromide, , lactate, mesylate, acetate,
trifluoroacetate, dichloroacetate, and citrate. Examples of counterions have been described
(e. g. Kumar et al., which is incorporated here in its entirety by reference). A compound or
an oligonucleotide of the invention may be prepared as a salt form f. Preferably, it is
ed in the form of its sodium salt. A compound or oligonucleotide of the present
invention may ally be further formulated in a composition which may be a
pharmaceutically acceptable on or composition containing pharmaceutically
accepted diluents and carriers, and to which pharmaceutically accepted ves may be
added to bring the ation to desired pH and/or osmolality, for example on or
dilution in sterile water or phosphate buffer and brought to desired pH with acid or base,
and to desired osmolality with organic or inorganic salts. For example, HCl may be used
to bring a solution to the desired pH, whereas NaCl may be used to bring a solution to
desired osmolality.
A pharmaceutical composition may comprise an excipient in enhancing the stability,
solubility, absorption, ilability, activity, pharmacokinetics, pharmacodynamics and
cellular uptake of said compound or oligonucleotide, in particular an excipient capable of
forming complexes, nanoparticles, microparticles, nanotubes, nanogels, hydrogels,
poloxamers or pluronics, polymersomes, colloids, microbubbles, vesicles, micelles,
lipoplexes, and/or liposomes. Examples of nanoparticles include polymeric nanoparticles,
gold nanoparticles, magnetic nanoparticles, silica nanoparticles, lipid nanoparticles, sugar
particles, protein nanoparticles and peptide nanoparticles.
In an embodiment a compound or an oligonucleotide ofthe invention may be used together
with another compound already known to be used for treating, ng and/or preventing
and/or treating and/or curing and/or ameliorating a human genetic disorder as myotonic
dystrophy type 1, spino-cerebellar ataxia 8 and/or Huntington’s disease-like 2 caused by
repeat expansions in the transcripts of PK, SCA8 or JPH3 genes tively.
Such other nd may be a steroid. This combined use may be a sequential use: each
component is administered in a distinct composition. Alternatively each compound may be
used together in a single ition.
In a method of the invention, we may use an excipient that will further aid in enhancing the
stability, solubility, absorption, bioavailability, activity, pharmacokinetics,
codynamics and delivery of said compound or oligonucleotide to a cell and into a
cell, in particular excipients capable of g complexes, vesicles, nanoparticles,
microparticles, nanotubes, nanogels, hydrogels, poloxamers or pluronics, polymersomes,
colloids, microbubbles, vesicles, es, exes and/or liposomes, that deliver
compound, substances and/or oligonucleotide(s) complexed or trapped in the vesicles or
liposomes through a cell membrane. Examples of nanoparticles include gold nanoparticles,
magnetic nanoparticles, silica rticles, lipid nanoparticles, sugar particles, protein
nanoparticles and peptide nanoparticles. Another group of delivery systems are polymeric
nanoparticles. Many of these substances are known in the art.
Suitable substances comprise polymers (e.g. hylenimine (PEI), ExGen 500,
polypropyleneimine (PPI), poly(2-hydroxypropylenimine (pHP)), dextran derivatives (e. g.
tions such like diethylaminoethylaminoethyl (DEAE)-dextran, which are well
known as DNA transfection reagent can be ed with butylcyanoacrylate (PBCA) and
hexylcyanoacrylate (PHCA) to formulate cationic nanoparticles that can deliver said
compound across cell membranes into cells), butylcyanoacrylate ,
yanoacrylate (PHCA), poly(lactic-co-glycolic acid) (PLGA), polyamines (e. g.
spermine, spermidine, putrescine, cadaverine), chitosan, poly(amido amines) (PAMAM),
poly(ester amine), polyvinyl ether, polyvinyl pyrrolidone (PVP), polyethylene glycol
(PEG) extrins, hyaluronic acid, colominic acid, and derivatives thereof), dendrimers
(eg. poly(amidoamine), lipids {e. g. l,2-dioleoyldimethylammonium propane
(DODAP), dioleoyldimethylammonium chloride (DODAC), phosphatidylcholine
derivatives [e.g 1,2- distearoyl-sn-glycerophosphocholine ], lysophosphatidylcholine
ties [ e.g. l-stearoyllyso-sn-glycerophosphocholine (SLysoPC
)], sphingomyeline, bis-(3-amino-propyl)-amino]-propylamino}-N—
ditetracedyl carbamoyl methylacetamide (RPR209120), phosphoglycerol derivatives [e. g.
l,2-dipalmitoyl-sn-glycerophosphoglycerol,sodium salt (DPPG—Na), phosphaticid acid
derivatives [l,2-distearoyl-sn-glycerophosphaticid acid, sodium salt (DSPA),
phosphatidylethanolamine derivatives [e.g. dioleoyl-L-R-phosphatidylethanolamine
(DOPE), l,2-distearoyl-sn-glycerophosphoethanolamine (DSPE),2-diphytanoyl-sn-
glycerophosphoethanolamine (DPhyPE)], N—[l-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium (DOTAP), l,3-di-oleoyloxy(6-carboxy-spermyl)-propylamid
(DOSPER), (l,2-dimyristyolxypropyldimethylhydroxy ethyl ammonium ),
(Nl -cholesteryloxycarbonyl-3,7-diazanonane- l ,9-diamine (CDAN),
dimethyldioctadecylammonium bromide (DDAB), l-palmitoyloleoyl-sn-glycerol
phosphocholine (POPC), (b-L-Arginyl-2,3-L-diaminopropionic acid-N—palmityl-N—olelyl-
amide trihydrochloride (AtuFECTOl), methylaminopropane derivatives [e.g.
l,2-distearoyloxy-N,N—dimethylaminopropane (DSDMA), oleyloxy-N,N—
dimethylaminopropane ), l,2-dilinoleyloxy-N,N—3-dimethylaminopropane
(DLinDMA), 2,2-dilinoleyldimethylaminomethyl [l,3]—dioxolane (DLin-K-DMA),
phosphatidylserine derivatives ioleyl-sn-glycerophospho-L-serine, sodium salt
(DOPS)], cholesterol}, synthetic amphiphils (SAINT-18), lipofectin, proteins (e. g.
albumin, gelatins, atellocollagen), peptides (eg. ,PepFects, NickFects, polyarginine,
sine, CADY, MPG),, combinations thereof and/or viral capsid proteins that are
capable of self assembly into particles that can deliver said compound or oligonucleotide to
a cell. Lipofectin represents an example of liposomal transfection agents. It consists of two
lipid components, a cationic lipid N—[l-(2,3-dioleoyloxy)propyl]-N,N,N—
trimethylammonium chloride (DOTMA) (cp. DOTAP which is the methylsulfate salt) and
a neutral lipid dioleoylphosphatidylethanolamine (DOPE). The neutral component
mediates the ellular release.
2012/050273
In addition to these nanoparticle materials, the cationic peptide protamine offers an
alternative approach to formulate said compound or oligonucleotide as colloids. This
colloidal nanoparticle system can form so called proticles, which can be prepared by a
simple self-assembly process to package and mediate intracellular release of a compound
as defined herein. The skilled person may select and adapt any of the above or other
commercially available or not commercially available alternative excipients and delivery
s to package and deliver a nd or oligonucleotide for use in the current
invention to deliver such compound or oligonucleotide for treating, preventing and/or
delaying of myotonic dystrophy type 1, cerebellar ataxia 8 and/or Huntington’s
e-like 2 in humans.
In addition, another ligand could be covalently or non-covalently linked to a compound or
oligonucleotide specifically designed to tate its uptake in to the cell, cytoplasm and/or
its nucleus. Such ligand could comprise (i) a compound (including but not limited to a
peptide(-like) structure) recognising cell, tissue or organ specific elements facilitating
cellular uptake and/or (ii) a chemical nd able to facilitate the uptake in to a cell
and/or the intracellular release of said compound or oligonucleotide from vesicles, e.g.
endosomes or lysosomes. Such targeting ligand would also encompass les
facilitating the uptake of said compound or oligonucleotide into the brain h the
blood brain barrier. Within the context of the invention, a peptide part of the compound of
the invention may already be seen as a ligand.
Therefore, in a preferred embodiment, a compound or an ucleotide as defined herein
is part of a medicament or is considered as being a medicament and is provided with at
least an ent and/or a targeting ligand for delivery and/or a delivery device of said
compound or oligonucleotide to a cell and/or enhancing its intracellular delivery.
Accordingly, the invention also encompasses a pharmaceutically acceptable ition
comprising said compound or oligonucleotide and further comprising at least one excipient
and/or a targeting ligand for ry and/or a delivery device of said compound to a cell
and/or enhancing its intracellular delivery.
However, due to the presence of a peptide part comprising LGAQSNF in a conjugate of
the invention, the use of such excipient and/or a ing ligand for delivery and/or a
delivery device of said compound to a cell and/or enhancing its intracellular delivery is
preferably not needed.
The invention also pertains to a method for alleviating one or more symptom(s) and/or
characteristic(s) and/or for improving a parameter of myotonic dystrophy type 1, spino-
cerebellar ataxia 8 and/or Huntington’s disease-like 2 in an individual, the method
comprising administering to said individual a compound or an oligonucleotide or a
pharmaceutical composition as defined herein.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its
non-limiting sense to mean that items following the word are included, but combinations
and/or items not cally mentioned are not excluded. In the context of the invention,
contains preferably means comprises.
In addition the verb “to consist” may be replaced by “to consist essentially of’ meaning
that a compound or a composition as defined herein may se additional ent(s)
than the ones specifically identified, said additional component(s) not altering the unique
characteristic of the ion.
The word “about” or “approximately” when used in association with a numerical value
(about 10) preferably means that the value may be the given value of 10 more or less 1% of
the value.
In addition, reference to an element by the indefinite article "a" or "an" does not exclude
the possibility that more than one of the element is present, unless the context clearly
2O es that there be one and only one of the elements. The ite e a or "an"
thus usually means "at least one".
The present invention is further described by the following examples which should not be
construed as limiting the scope of the invention.
Figure s
Figure 1. ts and conditions: a. maleimide propionic acid, HCTU, DIPEA, b.
TFA/HgO/TIS 95/25/25, ambient temperature, 4 h, c. Thiol modifier C6 S-S
phosphoramidite, ETT, d. PADS, 3-picoline, e. concentrated ammonium hydroxide
), 0.1M DTT, 55 0C, 16 h, f Sodium phosphate buffer 50 mM, lmM EDTA,
ambient temperature 16 h. The peptide (SEQ ID NO:2) is attached via its N terminus
(amino acid L) to the oligonucleotide. For this reason, in this figure the peptide is depicted
as FN8QAGL from C to N terminal. The resulting LGAQSNF-P858 is a conjugate
according to the first aspect of the ion. Herein, “P858” designates the
oligonucleotide part of said conjugate (SEQ ID NO: 1), which is (NAG)7 n N is C,
and which is a 2’-O-methyl phosphorothioate RNA. This conjugate can also be represented
by LGAQSNF/(CAG)7. Throughout the figures and the figure legends, “LGAQSNF-P858”
is used to indicate the conjugate as prepared by the process according to figure 1, and
“P858” is used to indicate an oligonucleotide consisting of (NAG)7 wherein N is C, and
which is modified with 2’-O-methyl phosphorothioate over its entire length, which is
optionally conjugated to a peptide or peptidomimetic part.
Figure 2. LGAQSNF/(CAG)7 ed ing of ed hDMPK transcripts in
DM500 cells. Northern blot analysis indicated that a peptide conjugated version of P858
(LGAQSNF-P858 or F/(CAG)7) was still fiinctional (lanes with PEI, number of
experiments (11) = 3, P<0.01) and was able to enter the cell nucleus g silencing of
expanded hDMPK transcripts without (w/o) the use of a transfection reagent (n=3,
P<0.001). Gapdh was used as g control.
Figure 3. Injection scheme intramuscular ion with LGAQSNF/P858 (CAG)7. Eight
2O DM500 mice were injected in the left GP8 x with LGAQSNF-P858
(LGAQSNF/(CAG)7). In the right GP8 complex four of these mice were injected with
P858 ((CAG)7) and four mice were injected with LGAQSNF-23 (“23” represents an
unrelated control AON (SEQ ID NO:3)). Mice were sacrificed and muscles were isolated
one (n=4 for F-P858 and n=2 for P858 and LGAQSNF-23) or three days (n=4
for LGAQSNF-P858 and n=2 for P858 and LGAQSNF-23) after the final injection.
Figure 4. LGAQSNF/(CAG)7 shows proof-of—concept in DM500 mice in vivo after
intramuscular injection. In DM500 mice, injection of LGAQSNF-P858
(LGAQSNF/(CAG)7) in the GP8 complex followed by quantitative RT-PCR analysis of
RNA content confirmed silencing of hDMPK (CUG)500 mRNA in the cnemius,
plantaris and soleus after LGAQSNF-P858 treatment compared to (A) P858 ((CAG)7,
SEQ ID NO: 1)) or (B) LGAQSNF-23 (“23” represents an unrelated control AON (SEQ ID
N03» treatment. (C) A significant reduction in all tissue was found when LGAQSNF-
P858 treatment was compared to both controls. (A-C) Data is grouped per tissue regardless
ofisolation day, two-tailed paired t-test, * P<0.05, ** P< 0.01, *** P<0.001.
Figure 5. Silencing capacities of modified AONs targeted towards the (CUG)n repeat.
Quantitative RT-PCR analysis indicated that P8387, (NAG)7 wherein N = 5-
methylcytosine (SEQ ID NO: 16) (n=3, P< 0.05), and P8613 (NAG)7XXXX wherein N=C
and X = 1,2-dideoxyribose abasic site (SEQ ID NO: 17) (n=3, P< 0.01) significantly
reduce mutant (CUG)n ripts in the in vitro DM500 cell model after transfection
compared to mock d cells (n=81). P858 ((CAG)7) (SEQ ID NO:1) was included as a
positive control (n=26, P<0.001). Gapdh and B-actin were used as loading control.
Figure 6. Synthesis of LGAQSNF/(NAG)7: a conjugate wherein the peptide (SEQ ID
NO: 2) is linked to a fiilly 2’-O-methyl phosphorothioate modified RNA oligonucleotide
(NAG)7, wherein N = C (SEQ ID NO: 1) (11) or ylcytosine (SEQ ID NO: 16) (12),
h a tional crosslinker. Reagents and conditions: a. TFA/HgO/TIS 95/25/25,
t temperature, 4 h, b. MIVIT-amino modifier C6 phosphoramidite, hiotetrazole,
c. PADS, line, d. conc. ammonium hydroxide, 55 0C, 16 h., e. AcOHzHZO (80:20
v:v), f DMSO-phosphate buffer, ambient temperature, 16 h., g. sodium phosphate buffer
(50 mM), lmM EDTA, ambient temperature, 16 h.
Figure 7. Comparative analysis of the activity of AONs designed to target the expanded
(CUG)n repeat in hDMPK (CUG)500 ripts in differentiated DM500 cells in vilro,
including (NAG)7 wherein N = C in P858 (SEQ ID NO: 1) or N = 5-methylcytosine in
P8387 (SEQ ID NO: 16), and (NZG)5 n N = C and Z = A in P8147 (SEQ ID NO:
18), or N = 5-methylcytosine and Z = A in P8389 (SEQ ID NO: 19), or N = C and Z = 2,6-
diaminopurine in PS388(SEQ ID NO:20), all at a fixed transfection concentration of 200
nM. Their activity, i.e. silencing of hDMPK transcripts, was fied by quantitative RT-
PCR using primers in exon 15. hDMPK transcript levels after AON treatment were
compared to the ve corresponding levels in the mock samples. For all AONs n=3
except for mock (n=8l), P858 (n=26). “n” represents the number of experiments carried
out. Statistical analysis was performed on AONs with similar length. The presence of 5-
methylcytosines had a cant positive effect on the activity of both the (CAG)5 and
(CAG)7 AONs. The presence of 2,6-diaminopurines allowed the shorter (CAG)5 AON to
have a similar activity as the longer (CAG)7 AON. Differences between groups were
considered cant when P<0.05. * ; ** P<0.0l; *** P<0.00l.
Figure 8. is of DM500 mice treated subcutaneously with F/(CAG)7
((CAG)7 is represented by P858; SEQ ID NO: 1) for four consecutive days at a 100 mg/kg
dose per day; one day after last injection. A l group was included in which the mice
were treated with LGAQSNF/control AON (the control AON is a led P858
sequence as represented by SEQ ID NO: 21). Levels of hDMPK (CUG)500 RNA were
quantified by Q-RT-PCR analysis with primers 5’of the (CUG)n repeat in exon 15.
Treatment with LGAQSNF-P858 (LGAQSNF/(CAG)7; as prepared with the process
according to figure 1; resulted both in gastrocnemius (A) as in heart (B) in a reduction of
expanded hDMPK levels compared to mice treated with LGAQSNF/control AON.
Differences between groups were ered significant when P<0.05. * P<0.05.
Figure 9. Analysis of HSALR mice treated subcutaneously with LGAQSNF/(CAG)7; as
prepared with the process according to figure 1 7 is represented by P858; SEQ ID
NO: 1) for five consecutive days at a 250 mg/kg dose per day; 4 weeks after last injection.
2O (A) EMG (electromyogram) measurements were performed on a weekly base by an
examiner blinded for mouse identity. A significant reduction in myotonia was observed in
gastrocnemius muscle in d mice as compared to saline-injected mice. (B) Northern
blot analysis revealed reduced levels of toxic (CUG)250 mRNA in gastrocnemius muscle in
treated mice compared to saline-injected mice. (C) RT-PCR analysis demonstrated a
reduction in embryonic splice mode (i.e. shift towards a more adult splicing pattern) of the
chloride channel (Clcnl); serca (Sercal) and titin (Ttn) transcripts in gastrocnemius muscle
of treated mice compared to saline-injected mice.
Figure 10. is of HSALR mice treated subcutaneously with LGAQSNF/(CAG)7; as
prepared with the process according to figure 1 ((CAG)7 is represented by P858; SEQ ID
NO: 1) by 11 injections of 250 mg/kg in a 4 week period; 4 days after the last injection.
Northern blot analysis trated that long-term treatment resulted in a significant
reduction of toxic (CUG)250 levels, both in gastrocnemius muscle (lOa, left graph) as in
tibialis anterior (10a, right graph graph) ed to saline-injected mice. RT-PCR
analysis demonstrated a reduction in embryonic splice mode (i.e. shift towards a more
adult splicing pattern) of the chloride channel ), serca (Sercal) and titin (Ttn)
transcripts in both gastrocnemius (10b, left graph) and tibialis anterior (10b, right graph
graph) muscles of treated mice compared to control. Differences between groups were
considered significant when P<0.05. * P<0.05, ** P<0.0l, *** P<0.00l.
Examples
Example 1: Synthesis PP08-PS58 conjugate
LGAQSNF-PSSS (LGAQSNF/(CAG)7, n (CAG)7 is represented by SEQ ID NO:1)
was sized following a ure adapted from the one of Ede NJ. et al. The
preparation ofLGAQSNF-PSSS conjugate is depicted in figure 1.
Peptide 1 (SEQ ID NO:2) was synthesized by standard Fmoc solid phase synthesis. On line
coupling of maleimide propionic acid, ed by deprotection and cleavage of the resin
with TFA:H20:TIS 25 and subsequent purification by reversed phase HPLC
afforded peptide 2 in 38% yield.
Thiol modifier C6 S-S phosphoramidite was coupled to oligonucleotide 3 via
phosphorothioate bond on solid t. Treatment of the crude resin with 40 % aqueous
ammonia and 0.1 M DTT led to the concomitant cleavage of the solid support,
deprotection of the nucleobases and reduction of the disulfide bond. Thiol containing
oligonucleotide 4 was isolated in 52 % yield after reversed phase HPLC purification.
Immediately before conjugate, nd 4 was applied to a PD-lO column with
phosphate buffer 50 mM, at pH=7. Eluted fractions containing the free thiol
oligonucleotide 4 were directly conjugated to peptide 2 (5 eq) via thiol-maleimide coupling
at room temperature for 16 hours. The crude was purified by reversed phase HPLC and
2O LGAQSNF-PS58 was isolated in 40 % yield.
EXPERIMENTAL PART
Chemicals
For peptide sis, Fmoc amino acids were purchased from Orpegen, 2-(6-Chloro-1H-
benzotriazole-l-yl)-l,1,3,3-tetramethylaminium hexafiuorophosphate ( HCTU) from PTI,
Rink amide IVfl3HA Resin from Novabiochem and 3-maleimidopropionic acid from
Bachem. For oligonucleotide synthesis, 2’-O-Me RNA phosphoramidites were obtained
from ThermoFisher and Modifier C6 S-S phosphoramidite was obtained from
ChemGenes. Custom Primer Support and PD-lO columns were from GE-Healthcare. 1,4-
threitol (DTT) and phenylacetyl disulfide (PADS) were purchased from Sigma-
Aldrich and American International Chemical, respectively.
W0 2012/144906
Peptide synthesis
The sis of peptide 1 was d out on a Tribute (Protein Technologies Inc.) peptide
synthesizer by standard Fmoc chemistry. Rink amide lVfl3HA resin (0.625 mmol/g, 160
mg, 100 umol) was used for the synthesis. Fmoc deprotection was accomplished using
% piperidine in ylpyrrolidone (NMP) and at every coupling 5 eq. Fmoc amino
acid, 5 eq. HCTU and 10 eq. MN—diisopropylethylamine (DIPEA) were added to the resin
and ng proceeded for 1 hour. After peptide sequence 1 was completed, 3-
maleimidopropionic acid (Seq) was coupled on line under the same conditions as
described before. Deprotection and cleavage from the resin was achieved using
trifiuoroacetic acid (TFA):H20:triisopropylsilane (TIS) 25 for 4 hours at room
temperature. The mixture was precipitated in cold diethylether and centrifuged. The
precipitate was purified by reversed phase (RP) HPLC on a SemiPrep Gilson HPLC
system: a C18 5 uM 150 mm X 22 mm, Buffer A: 95 % H20, 5 % ACN, 0.l %
TFA, Buffer B: 20 % H20, 80 % ACN, 0.1 % TFA. The fractions containing the pure
maleimide containing peptide were pooled and lyophilized to give peptide 2 (33.6 mg, 38
Oligonucleotide sis
2’-O-Me phosphorothioate oligonucleotide 3 was assembled on an AKTA prime OP-100
synthesiser using the protocols recommended by the supplier. Standard 2-cyanoethyl
phosphoramidites and Custom Primer Support (G, 40 umol/g) were used.
Ethylthiotetrazole (ETT,0.25 M in ACN) was used as coupling reagent and PADS (0.2 M
in ACN:3-picoline l:l v:v) for the sulfurization step. Oligonucleotide 3 was sized on
56 umol scale. After the oligonucleotide ce was completed, thiol modifier C6 S-S
phosphoramidite (4 eq) was incorporated on line at the 5’ terminus. The crude resin was
treated with 40 % aqueous ammonia containing 0.1 M DTT at 55 0C for 16 hours. The
solid support was filtrated and the filtrate evaporated to dryness. The crude was purified by
reversed phase HPLC on a SemiPrep Gilson HPLC system: a C18 5 uM 150 mm X
22 mm, Buffer A: 95 % H20, 5 % ACN, 0.1 M (tetraethylamonium acetate (TEAA),
Buffer B: 20 % H20, 80 % ACN, 0.1 M TEAA. The fractions containing the pure thiol
modified oligonucleotide were pooled and lyophilized. Compound 4 was isolated in 52 %
yield (29.2 umol).
W0 2012/144906
Synthesis of peptide-oligonucleotide conjugate LGAQSNF-PS58
Compound 4 (7 mmol) was applied to a PD-1O column pro-equilibrated with ate
buffer 50 mM, 1 mM EDTA pH=7. The eluted fraction containing the thiol oligonucleotide
was directly coupled to maleimide peptide (5 eq, 31 mg) and the reaction was continued at
room temperature for 16 hours. The crude was purified by reversed phase HPLC on a
SemiPrep Gilson HPLC system: Alltima C18 5 uM 150 mm X 22 mm, Buffer A: 95 %
H20, 5 % ACN, 0.1 M TEAA, Buffer B: 20 % H20, 80 % ACN, 0.1 M TEAA. The
fractions containing the pure ate were pooled, NaCl was added and the solvents
were evaporated to dryness. Desalting was lished through elution on a PD-1O
brated with water. After desalting, the pooled fractions were lyophilized to give
LGAQSNF-PS58 (25.1 mg, 2.8 umol, 40% yield)
MATERIALS AND METHODS
Animals. Hemizygous DM500 mice - derived from the DM300-328 line (Seznec H. et al) -
express a transgenic human DMl locus, which bears a repeat segment that has expanded to
2O approximately 500 CTG triplets, due to intergenerational triplet repeat instability. For the
isolation of al DM500 myoblasts, DM500 mice were crossed with H-2Kb-tsA58
transgenic mice (Jat PS. et al). All animal experiments were approved by the Institutional
Animal Care and Use Committees of the Radboud University Nijmegen.
Cell culture. alized DM500 myoblasts were derived from DM300-328 mice
(Seznec H. et al) and cultured and differentiated to myotubes as described before (Mulders
S.A. et al).
Oligonucleotides. AON P858 ((CAG)7, SEQ ID NO: 1) was described before (Mulders
S.A. et al). The conjugate LGAQSNF was coupled to the 5’ end of AON P858 or control
AON 23 (5'-GGCCAAACCUCGGCUUACCU-3': SEQ ID NO:3) (Duchenne Muscular
Dystrophy (DMD) AON). These AONs were ed by Prosensa Therapeutics B.V.
(Leiden, The Netherlands). P8387 7 wherein N = 5-methylcytosine, SEQ ID
NO: 16) and P8613 ((NAG)7 XXXX wherein N=C and X is a 1,2-dideoxyribose abasic site
attached to the 3’ terminus of the oligo) (SEQ ID NO: 17)) were synthesized by Eurogentec
(tthe Netherlands).
Transfection. All AONs were tested in presence of transfection reagent and LGAQ8NF-
P858 was also tested in the absence of transfection reagent. AONs were transfected with
polyethyleneimine (PEI) (EXGen 500, Fermentas, Glen Burnie, MD), according to
manufacturer’s instructions. Typically, 5 uL PEI solution per ug AON was added in
entiation medium to myotubes on day five of myogenesis at a final oligonucleotide
concentration of 200 nM. Fresh medium was supplemented to a maXimum volume of 2 mL
after four hours. After 24 hours medium was changed. RNA was isolated 48 hours after
transfection. LGAQ8NF-P858 was tested following the ol above with the exception
that no transfection reagent was used.
RNA isolation. RNA from cultured cells was isolated using the Aurum Total RNA Mini
Kit (Bio-Rad, Hercules, CA) according to the manufacturer's protocol. RNA from muscle
tissue was isolated using TRIzol reagent (Invitrogen). In brief, tissue samples were
homogenized in TRIzol (100 mg tissue/mL ) using a power homogenizer (ultra
TURRAX T-8, IKA labortechnik). Chloroform (Merck) was added (0.2 mL per mL
TRIzol), mixed, ted for 3 minutes at room ature and centrifuged at 13,000
rpm for 15 s. The upper aqueous phase was collected and 0.5 mL isopropanol
(Merck) was added per 1 mL TRIzol, followed by a 10 min incubation period at room
temperature and centrifugation (13,000 rpm, 10 min). The RNA precipitate was washed
with 75% (v/v) ethanol (Merck), air dried and dissolved in MilliQ.
Northern blotting. Northern blotting was done as described (Mulders 8.A. et al).
Random-primed beled hDMPK (2.6 kb) and rat Gapdh (1.1 kb) probes were used.
8ignals were quantified by phospho-imager analysis (GS-505 or Molecular Imager FX,
Bio-Rad) and analyzed with ty One (Bio-Rad) or ImageJ software. Gapdh levels
were used for ization, RNA levels for control samples were set at 100.
In vivo treatment and muscle isolation. Seven month old DM500 mice were anesthetized
using ane. The GPS (gastrocnemius-plantaris-soleus) complex was injected on day
one and two at the same central position in the GPS muscle with 4 nmoles LGAQSNF-
PS58, LGAQSNF-23 or PS58 (SEQ ID NO:1) in a saline on (0.9% NaCl). In all
cases, injection volume was 40 uL. Mice were ced one or three days after final
injection and dual muscles were isolated, snap frozen in liquid nitrogen and stored at
-80 CC.
Quantitative RT-PCR analysis. Approximately 1 ug RNA was subjected to cDNA
synthesis with random hexamers using the SuperScript first-strand synthesis system
(Invitrogen) in a total volume of 20 uL. 3 HL of 1/500 cDNA dilution ation was
subsequently used in a quantitative PCR analysis according to standard ures in
presence of 1>< FastStart Universal SYBR Green Master (Roche). Quantitative PCR
primers were designed based on NCBI database sequence information. Product identity
was confirmed by DNA sequencing. The signal for B-actin and Gapdh was used for
normalization. Amplification was performed on a Corbett Life Science Rotor-Gene 6000
using the following 2 step PCR protocol: ration for 15 min at 95 0C and 40 cycles of
s 95 0C and 50 s 60 0C. SYBR Green fluorescence was ed at the end of the
extension step (60 0C). After amplification, amplified DNA was dissociated by a melt from
64 0C to 94 0C. SYBR Green fluorescence was measured during this step to confirm single
amplicon amplification. Serial dilutions of cDNA standards were used to determine the
efficiency of each primer set. Critical cycle old (Ct) values were determined using
Gene 6000 Series Software (Corbett Research), the expression of the gene of interest
(GOI) was normalized against B-actin and Gapdh and expressed as the ratio to the
correspondent control, using formulas according to the AACt method. The following
primers were used:
hDMPK exon 15 (5’)-F, 5’- AGAACTGTCTTCGACTCCGGG—3’ (SEQ ID NO:4),
hDMPK exon 15 (5’)-R, 5’-TCGGAGCGGTTGTGAACTG—3’ (SEQ ID NO:5),
B-Actin-F, 5’- GCTCTGGCTCCTAGCACCAT-3’(SEQ ID NO:6),
B-Actin-R, 5’- GCCACCGATCCACACAGAGT-3’ (SEQ ID NO:7),
Gapdh-F, 5’- GTCGGTGTGAACGGATTTG-3’ (SEQ ID NO:8),
Gapdh-R, 5’- GAACATGTAGACCATGTAGTTG—3’ (SEQ ID NO:9),
WO 44906
RESULTS
Silencing of hDMPK (CUG)500 RNA by LGAQSNF-P858 in an in vitro DMl model.
Northern blotting revealed a ~90% silencing of hDMPK transcripts after treatment of
DM500 cells with LGAQSNF-P858 in presence of transfection t (PEI), confirming
onality of peptide conjugated P858. The same level of mutant hDMPK mRNA
reduction was found when LGAQSNF-P858 was added to DM500 cells in absence of
transfection reagent indicating that LGAQSNF was responsible for cellular and nuclear
uptake of P858 (Figure 2).
Intramuscular injections of LGAQSNF-P858 causes silencing of expanded hDMPK
transcripts in vivo. DM500 mice were injected intramuscular (I.M.) in the GPS complex
with LGAQSNF-P858 to reveal functionality of the peptide conjugated version of P858 in
viva. As control, unconjugated P858 and LGAQSNF coupled to a DMD control AON 23
(SEQ ID NO: 3) (LGAQSNF-23) were included. Mice were treated for two days with one
IM. injection daily and tissue was ed on day one or three after the final injection
(Figure 3). Quantitative RT-PCR analysis indicated no statistically significant difference
n tissue isolation days so data of both ion days were grouped. Q-RT-PCR
analysis showed a significant reduction of hDMPK mRNA levels after treatment of
2O F-P858 ed to unconjugated P858 in both gastrocnemius (55%) and
plantaris (60%), and a reduction of 28% was found in soleus e 4A). A ~50%
silencing of hDMPK (CUG)500 levels was found in all individual tissues of the GPS
complex after LGAQSNF-P858 treatment compared to LGAQSNF-23 (Figure 4B).
Because hDMPK transcript levels did not differ significantly between controls, mutant
DMPK mRNA levels after LGAQSNF-P858 treatment were related to both P858 and
LGAQSNF-23 (Figure 4C). In all individual tissue of the GPS x tested LGAQSNF-
P858 was sible for silencing of hDMPK (CUG)500 levels not seen after control
treatment.
A compound with an oligonucleotide part (CAG)7 linked to an abasic site causes a
significant increase of the efficiency of silencing of expanded hDMPK (CUG)500
transcripts in vitro compared to the efficiency of a counterpart nd not having
said abasic site.
DMSOO cells were transfected with 200 nM P8387, P8613 and P858. Quantitative RT-
PCR analysis revealed that both modified AONs (P8387 and P8613) caused a significant
silencing of mutant (CUG)500 hDMPK transcripts compared to control treated cells (mock).
P858 was included as a positive l (Figure 5).
EXAMPLE 3
Synthesis of peptide-2’-0—Me phosphorothioate RNA oligonucleotide conjugate
LGAQSNF-(NGA)7, wherein N=C 0r S-methylcytosine, through a bifunctional
crosslinker.
2’-O-Me phosphorothioate (PS) RNA oligonucleotide conjugate LGAQSNF-(NAG)7 in
which N = C (SEQ ID NO: 1) or 5-methylcytosine (m5C) (SEQ ID NO: 16) was prepared
following the ation method depicted in Figure 6. This conjugation method relies on
the coupling of a 5’ amino-modified oligonucleotide (6, 7) to a heterobifunctional
crosslinker 8 providing a maleimide-modifled oligonucleotide (9, 10), which can be
coupled to a thiol-functionalized peptide.
The peptide was assembled on solid t following standard Fmoc peptide synthesis
procedures. To e the e with a thiol functionality for enabling coupling of the
peptide to the oligonucleotide, a cysteine residue was added to the N-terminus of the
peptide. Subsequent acidic cleavage and deprotection afforded peptide 5, whose N-
terminus could be prepared as free amine (5a) or as an acetamide group (5b) through
capping by acetylation after introduction of the last amino acid.
A thoxytrityl (MMT)-protected no modifier phosphoramidite (Link
Technologies) was coupled on-line to the 5’ of the led (NAG)7 2’-O-Me PS RNA
oligonucleotide ce (N = C or 5-methylcytosine). Cleavage from the solid support
and concomitant deprotection of the nucleobases by a two steps basic treatment
[diethylamine (DEA) and then ammonia] and subsequent acid ent to remove the
WT ting provided amino-modified oligonucleotides 6 and 7.
Reaction of 6 and 7 with B-maleimidopropionic acid succinimide ester (BMPS, 8), a
heterobifunctional crosslinker carrying succinimide and maleimide functional groups,
afforded maleimide-equipped ucleotides 9 and 10, respectively. Peptide-
oligonucleotide conjugation was effected through maleimide coupling of thiol-labeled
peptides 5 with maleimide-derived oligonucleotides 9 and 10.
Peptide synthesis
The peptide sequence CLGAQSNF was assembled on a Tribute peptide synthesizer
(Protein Technologies) by standard Fmoc chemistry employing Rink amide lVfl3HA resin
W0 2012/144906 2012/050273
(0.625 mmol/g, 160 mg, 100 umol, NovaBiochem) as described in Example 1. After
completion of the peptide synthesis, a final capping step (acetic anhydride (AC2O),
pyridine) was performed (5b) or omitted (5a). Deprotection and cleavage from the resin
was achieved using TFA:H2O:TIS 95:25:25 (v:v:v) for 4 h at ambient temperature. The
mixture was d, precipitated in cold diethyl ether, centrifuged and the supernatant was
discarded. Both crude precipitated peptide or RP-HPLC purified peptide were used for the
conjugations.
Oligonucleotide synthesis
2’-O-Me phosphorothioate RNA oligonucleotides (NAG)7 (wherein N = C (SEQ ID NO: 1)
or 5-methylcytosine (SEQ ID NO: 16)) were led on an AKTA Prime OP-100
synthesizer (GE) as described in example 1. After the oligonucleotide sequences were
completed, MlVlT-C6-amino-modifier phosphoramidite was incorporated on-line at the 5’
terminus. The crude resins were then first washed with DEA and then with 29% aqueous
ammonia at 55°C for 16 h. for cleavage and deprotection of base-labile protecting groups.
The reaction mixture was filtered and the solvent was removed by evaporation. The
ucleotides were treated with 80 mL acetic acid : H2O , v:v) and
shaken for 1 h at ambient temperature to remove the MMT group, after which the solvents
were removed by evaporation. The crude mixtures were dissolved in 100 mL H20 and
washed with ethyl acetate (3 x 30 mL). The water layer was concentrated and the residue
was d with RP-HPLC either on a Gilson GX-271 system [C13 Phenomenex Gemini
axia NX C-18 5 um column (150 x 21.2 mm), buffer A: 95% H20, 5% ACN, 0.1 M
TEAA, solvent B: buffer B: 20% H20, 80% ACN, 0.1 M TEAA. Gradient: 10-60% Buffer
B in 20 min] or IEX ions on a Shimadzu Prominence preparative system
[polystyrene Strong Anion Exchange, Source 30Q, 30 pm (100 x 50 mm). Eluents A: 0.02
M NaOH, 0.01 M NaCl, Eluens B: 0.02 M NaOH, 3 M NaCl. Gradient 0 to 100% B in 40
min]. 70 uL of 100 mM BMPS (8, 7 equiv.) in dimethylsulfoxide (DMSO) was added to 1
umol amino-modified ucleotide (6, 7) in 280 uL phosphate buffer (containing 20%
ACN). The reaction mixture was shaken at ambient temperature for 16 h. After filtration
over Sephadex G25, 5’-maleimide d ucleotides 9 and 10 were obtained.
WO 44906 2012/050273
Peptide oligonucleotide conjugation
Peptide CLGAQSNF (5a or 5b, 10 equiv.) was added to the 5’-malemide modified
ucleotide (9 or 10, 1 pmol) in 3.5 mL phosphate buffer and the reaction mixture was
shaken at t temperature for 16 h. After centrifugation, the supernatant was purified
by reversed-phase HPLC on a ence HPLC (Shimadzu) [Alltima C18 column (5 um,
x 250 mm), buffer A: 95% H20, 5% ACN, 0.1 M tetraethylammonium acetate (TEAA),
buffer B: 20% H20, 80% ACN, 0.1 M TEAA]. Fractions containing the pure conjugates
were pooled, NaCl was added and the solvents were evaporated. Desalting was
accomplished on a Sephadex G25 column equilibrated with water. After desalting, the
pooled fractions were lyophilized to provide the final conjugates. LCMS (ESI, negative
mode) analysis revealed the correct mass: 10a (N=C, R=H, Figure 6) ated: 8595.3,
Found 8595.4, 10b (N=5-methylcytosine, R=Ac) Calculated: , Found: 8735.4.
EXAMPLE 4
Introduction
The particular characteristics of a chosen AON chemistry may at least in part enhance
binding affinity and stability, enhance activity, improve safety, and/or reduce cost of goods
by reducing length or improving synthesis and/or purification procedures. This e
describes the ative analysis of the activity of AONs designed to target the expanded
(CUG)n repeat in hDMPK (CUG)500 transcripts in differentiated DM500 cells in vilro, and
includes AONs with 5-methylcytosines (PS3 87 (SEQ ID NO: 16 and PS3 89 (SEQ ID NO:
19)) or 2,6-diaminopurines (PS388, SEQ ID NO: 20) versus corresponding AONs (PS147
(SEQ ID NO: 18) and PS58 (SEQ ID NO:1)) without this base modification.
Materials and Methods
Cell culture. Immortalized DM500 myoblasts were derived from DM300-328 mice
(Seznec H. el al.) and cultured and differentiated to myotubes as described before (Mulders
S.A. el al.) In short, DM500 myoblasts were grown on gelatine-coated dishes in high
serum DMEM at 33 oC. Differentiation to myotubes was d by placing DM500
myoblasts, grown to confiuency on Matrigel, in low serum DMEM at 37 oC.
Oligonucleotides. AON P858 (CAG)7) was described before (Mulders 8A. el al.) AONs
used were fully 2’-O-methyl phosphorothioate modified: P8147 (NZG)5 in which N = C
and z = A (SEQ ID NO: 18), PS3 89 (NZG)5 (SEQ ID NO: 19) and PS3 87 (NZG)7 in
which N = 5-methylcytosine (SEQ ID NO: 16) and Z = A, and PS3 88 (NZG)5 in which N
= C and Z = 2,6-diaminopurine (SEQ ID NO:20).
Transfection. Cells were transfected with AONs complexed with PEI (2 uL per ug AON,
in 0.15 M NaCl). AON-PEI complex was added in differentiation medium to myotubes on
day five of myogenesis at a final oligonucleotide concentration of 200 nM. Fresh medium
was mented to a m volume of 2 mL after four hours. After 24 hours medium
was changed. RNA was isolated 48 hours after transfection.
RNA ion. RNA from cultured cells was isolated using the Aurum Total RNA Mini
Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol.
Quantitative RT-PCR analysis. Approximately 1 ug RNA was used for cDNA synthesis
with random hexamers using the SuperScript f1rst-strand synthesis system (Invitrogen) in a
total volume of 20 ul. 3 uL of 1/500 cDNA dilution preparation was subsequently used in
a quantitative PCR analysis according to standard procedures in presence of IX FastStart
2O Universal SYBR Green Master (Roche). Quantitative PCR primers were designed based on
NCBI database sequence information. Product identity was confirmed by DNA
sequencing. The signal for n and Gapdh was used for ization as described in
example 2.
Results
Quantitative RT-PCR analysis demonstrated that all tested AONs induced a significant
silencing of hDMPK transcripts after AON ent when compared to mock treated cells
(Figure 7). The presence of 5-methylcytosines had a significant positive effect on the
activity of both the (CAG)5 (P8147) and (CAG)7 (P858) AONs. The presence of 2,6-
opurines d the shorter (CAG)5 AON (P8147) to have a r activity as the
longer (CAG)7 AON (P858).
EXAMPLE 5
Introduction
ic Dystrophy type 1 (DMD is a complex, multisystemic e. For AONs to be
clinically effective in DMl, they need to reach a wide variety of tissues and cell types
therein. A new compound was ed based on ation of peptide LGAQSNF to
P858 for improved activity, ing and/or delivering to and/or uptake by multiple tissues
including heart, skeletal and smooth muscle. This example demonstrates its in vivo eff1cacy
on silencing of toxic DMPK transcripts following systemic treatment ofDM500 mice.
Materials and s
Animals. Hemizygous DM500 mice - derived from the DM300-328 line c H. el al.)
- s a transgenic human DMl locus, which bears a repeat segment that has expanded
to imately 500 CTG triplets, due to intergenerational triplet repeat instability. All
animal experiments were approved by the Institutional Animal Care and Use Committees
ofthe Radboud University en.
Oligonucleotides. The peptide LGAQSNF was coupled to the 5’ end of AON P858
(CAG)7 (SEQ ID NO: 1) or to a control AON (scrambled P858, 5’-
CAGAGGACCACCAGACCAAGG—‘3, SEQ ID NO:21), as described in example 1.
In vivo treatment. DM500 mice were injected subcutaneously in the neck region with 100
mg/kg LGAQSNF-P858 or LGAQSNF-control AON. Injections were given for four
consecutive days and tissue was isolated one day after the final injection.
RNA isolation. RNA from tissue was isolated using TRIzol reagent (Invitrogen). In brief,
tissue samples were homogenized in TRIzol (100 mg tissue/mL TRIzol) using a power
homogenizer (ultra TURRAX T-8, IKA labortechnik). Chloroform (Merck) was added (0.2
mL per mL TRIzol), mixed, incubated for 3 minutes at room temperature and centrifuged
at 13,000 rpm for 15 minutes. The upper aqueous phase was collected and 0.5 mL
isopropanol (Merck) was added per 1 mL TRIzol, followed by a 10 min incubation period
at room temperature and centrifugation (13,000 rpm, 10 min). The RNA itate was
washed with 75% (v/v) l (Merck), air dried and dissolved in .
Quantitative RT-PCR analysis. Approximately 1 ug RNA was subjected to cDNA
synthesis with random hexamers using the 8uper8cript first-strand synthesis system
(Invitrogen) in a total volume of 20 uL. 3 uL of 1/500 cDNA dilution preparation was
subsequently used in a quantitative PCR analysis according to standard procedures in
ce of IX Fast8tart Universal SYBR Green Master (Roche). Quantitative PCR
primers were designed based on NCBI database sequence information. Product identity
was ed by DNA sequencing. The signal for B-actin and Gapdh was used for
normalization as described in example 2.
Quantitative RT-PCR is demonstrated that systemic treatment with LGAQSNF-
P858 resulted in a significant reduction of expanded hDMPK (CUG)500 transcripts in
DM500 mice when compared to mice treated with F-control AON. In both
gastrocnemius and heart muscles an overall ~40% reduction of hDMPK levels was found
(Figure 8), indicating that the peptide LGAQSNF promoted delivery and/or activity of
P858 in two target organs affected in DMl.
EXAMPLE 6
Introduction
Myotonic Dystrophy type 1 (DMl) is a complex, multisystemic disease. For AONs to be
clinically effective in DMl, they need to reach a wide variety of tissues and cell types
therein. A new compound was designed based on conjugation of peptide LGAQSNF to
P858 for ed activity, targeting and/or delivering to and/or uptake by multiple tissues
including heart, skeletal and smooth muscle. This e trates its in vivo efficacy
in HSALR mice. These mice, expressing a toxic (CUG)250 repeat in a human skeletal actin
transgene, not only show molecular deficits similar to DMl patients but also display a
myotonia phenotype.
Materials and Methods
Animals. Homozygous HSALR mice (line HSALR20b) express 250 CTG repeats within the
3’ UTR of a transgenic human skeletal u-actin gene di A. el al.) HSALR mice
develop ribonuclear inclusions, myotonia, myopathic features and ogical muscle
changes similar to DM1. All animal experiments were approved by the Institutional
Animal Care and Use Committees of the Radboud University en.
Oligonucleotides. The peptide LGAQSNF was coupled to the 5’ end of AON P858
(CAG)7 (SEQ ID NO: 1) as described in example 1.
In vivo treatment. HSALR mice were injected subcutaneously in the neck region with
LGAQSNF-PSSS for five consecutive days at a dose of 250 mg/kg, and compared to
control mice that received saline injections only. EMG measurements were performed on a
weekly base and tissue was isolated four weeks after the first injection.
EMG. EMG was performed under general anaesthesia. A minimum of 5-10 needle
insertions were performed for each muscle examination. Myotonic discharges were graded
on a 4-point scale: 0, no ia, 1, occasional myotonic discharge in less than 50% of
needle insertions; 2, myotonic discharges in r than 50% of needle insertions, 3,
myotonic discharge with nearly every insertion
RNA isolation. RNA from tissue was isolated using TRIzol reagent rogen). In brief,
tissue samples were homogenized in TRIzol (100 mg tissue/mL TRIzol) using a power
homogenizer (ultra TURRAX T-8, IKA echnik). form (Merck) was added (0.2
mL per mL TRIzol), mixed, incubated for 3 minutes at room temperature and centrifuged
at 13,000 rpm for 15 minutes. The upper aqueous phase was collected and 0.5 mL
isopropanol (Merck) was added per 1 mL TRIzol, followed by a 10 min incubation period
at room ature and centrifugation (13,000 rpm, 10 min). The RNA precipitate was
washed with 75% (v/v) ethanol ), air dried and dissolved in MilliQ.
Northern blotting. RNA was electrophoresed in a 1.2% e-formaldehyde denaturing
gel loaded with one ug RNA per lane. RNA was transferred to -XL nylon
ne (Amersham Pharmacia Biotech, Little Chalfont, UK) and hybridized with 32P-
end-labeled (CAG)9 or mouse skeletal actin-specific (MSA) oligos. Blots were exposed to
X-ray film (Kodak, X-OMAT AR). Quantification of signals was done by phospho-imager
analysis (GS-505 or Molecular Imager FX, Bio- Rad) and analyzed with Quantity One
(Bio-Rad) or ImageJ software. MSA levels were used for normalization.
Semi-quantitative RT-PCR analysis. Approximately 1 ug RNA was used for cDNA
synthesis with random hexamers using the SuperScript trand synthesis system
(Invitrogen) in a total volume of 20 uL. One ul of cDNA preparation was subsequently
used in a semi-quantitative PCR analysis according to standard procedures. In RT- control
experiments, reverse transcriptase was omitted. Product identity was confirmed by DNA
sequencing. PCR products were ed on 15-25% agarose gels, stained by ethidium
bromide. Quantification of signals was done using the Labworks 4.0 software (UVP
BioImaging systems, Cambridge, United Kingdom). For analysis of alternative splicing,
embryonic (E): adult (A) splice ratio was defined as embryonic form signal divided by
adult form signal in each sample. Splice ratio correction illustrates the effect of
LGAQSNF-PS58 treatment on alternative splicing (i.e., Sercal, Ttn and . The
2O following primers were used:
-F, 5’- GGTCCTCAAGATCTCAC-3’ (SEQ ID NO: 22)
Sercal-R, 5’- GGGTCAGTGCCTCAGCTTTG—3’ (SEQ ID NO: 23)
Ttn-F, 5’- GTGTGAGTCGCTCCAGAAACG—3’ (SEQ ID NO: 24)
Ttn-R, 5’- CAGGACCATGTTATTTC-3’ (SEQ ID NO, 25)
Clcnl-F, 5’- CCTCACACTCAAGGCC-3’ (SEQ ID NO: 26)
Clcnl-R, 5’- CACGGAACACAAAGGCACTGAATGT-3’ (SEQ ID NO: 27)
Results
Four weeks after the first injection, EMG measurements in the gastrocnemius muscles
revealed a significant, but mild, reduction in myotonia in LGAQSNF-PS58 treated mice
when compared to saline-treated mice (Figure 9A). This reduction in myotonia was
paralleled by a ~50% reduction in toxic (CUG)250 transcript levels (Figure 9B), and a shift
in ng pattern form an embryonic-like (E) to normal-adult (A) mode for Clcnl, Serca l
and Ttn transcripts (Figure 9C) in the gastrocnemius s. These results indicate that
the peptide LGAQSNF indeed promoted ry and/or activity of P858 in muscle in viva,
both on molecular and phenotypic level.
EXAMPLE 7
Introduction
This example again demonstrates the in vivo efficacy of LGAQSNF-P858 in HSALR mice.
The mice were here treated for a prolonged period of time. Silencing of toxic (CUG)250
transcripts and splicing pattern shifts of downstream genes were monitored and compared
to those in saline-treated mice.
Materials and Methods
Animals. gous HSALR mice (line HSALRZOb) express 250 CTG repeats within the
3 ‘UTR of a transgenic human skeletal d-actin gene (Mankodi A. el al.) HSALR mice
develop ribonuclear inclusions, myotonia, myopathic features and histological muscle
changes similar to DMl. All animal experiments were approved by the Institutional
Animal Care and Use tees of the Radboud University Nijmegen.
ucleotides. The peptide LGAQSNF was coupled to the 5’end of AON P858
(CAG)7 (SEQ ID NO: 1) as described in example 1.
In vivo treatment. HSALR mice that received eleven subcutaneous injections of 250 mg/kg
LGAQSNF-P858 in the neck region in a four weeks period were compared to mice that
were injected with saline only. Thirty-two days after the first injection all mice were
iced and tissue was isolated.
RNA ion. RNA from tissue was isolated using TRIzol reagent (Invitrogen). In brief,
tissue samples were homogenized in TRIzol (100 mg tissue/mL TRIzol) using a power
homogenizer (ultra TURRAX T-8, IKA echnik). Chloroform (Merck) was added (0.2
mL per mL TRIzol), mixed, ted for 3 minutes at room temperature and centrifuged
at 13,000 rpm for 15 minutes. The upper aqueous phase was collected and 0.5 mL
isopropanol (Merck) was added per 1 mL TRIzol, followed by a 10 min incubation period
at room temperature and centrifugation (13,000 rpm, 10 min). The RNA precipitate was
washed with 75% (v/v) ethanol (Merck), air dried and dissolved in MilliQ.
Northern blotting. RNA was electrophoresed in a 1.2% agarose-formaldehyde denaturing
gel loaded with one ug RNA per lane. RNA was transferred to Hybond-XL nylon
membrane (Amersham Pharmacia Biotech, Little Chalfont, UK) and ized with 32P-
end-labeled (CAG)9 or mouse skeletal actin-specif1c (MSA) oligos. Blots were exposed to
X-ray film (Kodak, X-OMAT AR). Quantification of signals was done by phospho-imager
is (GS-505 or Molecular Imager FX, Bio- Rad) and analyzed with Quantity One
(Bio-Rad) or ImageJ software. MSA levels were used for normalization.
Semi-quantitative RT-PCR analysis. Approximately 1 ug RNA was used for cDNA
synthesis with random hexamers using the SuperScript first-strand synthesis system
(Invitrogen) in a total volume of 20 uL. One ul of cDNA preparation was subsequently
used in a uantitative PCR is according to standard procedures. In RT- control
experiments, e transcriptase was omitted. Product identity was confirmed by DNA
sequencing. PCR products were analyzed on 15-25% agarose gels, d by ethidium
bromide. fication of s was done using the Labworks 4.0 software (UVP
BioImaging systems, dge, United Kingdom). For analysis of alternative splicing,
embryonic (E): adult (A) splice ratio was d as embryonic form signal divided by
adult form signal in each sample. Splice ratio correction illustrates the effect of
LGAQSNF-PS58 treatment on alternative splicing (i.e., Serca1, Ttn and Clcnl). The
following primers were used:
Sercal-F, 5’- GCTCATGGTCCTCAAGATCTCAC-3’ (SEQ ID NO: 22)
Sercal-R, 5’- GGGTCAGTGCCTCAGCTTTG—3’ (SEQ ID NO: 23)
Ttn-F, 5’- GTGTGAGTCGCTCCAGAAACG—3’ (SEQ ID NO: 24)
Ttn-R, 5’- CCACCACAGGACCATGTTATTTC-3’ (SEQ ID NO: 25)
Clcn1-F, 5’- CCTCACACTCAAGGCC-3’ (SEQ ID NO: 26)
Clcn1-R, 5’- CACGGAACACAAAGGCACTGAATGT-3’ (SEQ ID NO: 27)
2012/050273
Results
Thirty-two days after the first ion, HSALR mice were sacrificed and tissue was
isolated. Northern blotting showed a significant reduction in toxic (CUG)250 levels both in
the cnemius (Figure 1021, left graph) and tibialis anterior (Figure 1021, right graph)
muscles of LGAQSNF-PSSS treated mice when compared to those in saline-treated mice.
In both muscle groups an average (CUG)250 ion of ~50% was found. This reduction
was paralleled by a shift from an embryonic-like (E) to normal-adult (A) splicing pattern
for Clcnl, Serca 1 and Ttn transcripts both in gastrocnemius (Figure 10b, left graph) and
tibilais anterior (Figure 10b, right graph) muscles. These results again indicate that the
peptide LGAQSNF promotes delivery and/or activity of P858 in muscle in viva.
WO 44906
Table 1: Oligonucleotides and peptides used in experimental part
Name AON Sequence (5’93’) SEQ ID NO
P558 (CAG)7 1
PP08 LGAQSNF 2
“23” control AON GGCCAAACCUCGGCUUACCU 3
(NAG)7
P5387 16
N = 5-methy1cyt051ne.
(NAG)7XXXX
P5613 N = C 17
X = 1,2—dideoxyribose abasic site
(NZG)5
P5147 18
N = C and Z = A
(NZG)5
P5389 19
N = 5-methy1cytosine and Z = A
(NZG)5
P5388 20
N = C and Z = 2,6-diaminopurine
scrambled P558 CAGAGGACCACCAGACCAAGG 21
Reference list
Braida C. et al, Human Molecular Genetics, (2010), V019: 412.
Ede, N.J., Tregear, G.W., Haralambidis, J. Bioconj. Chem. 1994,5,373-378.
Harper PS (1989) Myolom'c Dystrophy (Saunders, W. B., Philadelphia).
Hebert et a1. BMC Musculoskeletal Disorders 2010, 11:72.
Hongquing D. et a1., Nature structural & molecular biology 2010, 17: 141-142
Januario et a1, and Rehabilitation, 2010, 32(21): 1775—1779
, Disability
Jat PS, el al. (1991). Proc NaZlAcadSci USA 88:5096-5100.
Kumar L, Pharm. Technol. 2008, 3, 128.
Mahant et a1, Neurology. 2003,61(8):1085-92
Mankodi A. et a1., The journal of l physiology 2007,129(1):79-94.
Mulders SA, el al. (2009) Proc NallAcad Sci USA 106: 13915-13920.
Nakamura et al, l of the ogical Sciences 278 (2009) 107—1 11
Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, MD:
Lippincott Williams & s, 2000.
Seznec H, el al. (2000). Hum M0] Genet 9:1185-1194.
Taneja KL et a1., Journal of cell biology 1995, 128: 995-1002
Tones C. et al., Journal of neurological sciences. 1983;60:157-168
Trouillas P. et al, J. Neurol. Sci, 1997: 145: 205-211
Walker, 2007 LANCET 369; p.218-228
Wiles, et al, J Neurol urg Psychiatry 2006;77:393-396
Claims (19)
1. Compound comprising a peptide part comprising LGAQSNF linked to an oligonucleotide part comprising (NAG)m in which N is C or 5-methylcytosine, and n m is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
2. Compound according to claim 1, wherein the length of the oligonucleotide part comprising (NAG)m, in which N is C or ylcytosine, is from 12 to 45 nucleotides.
3. Compound according to claim 1 or 2, wherein the oligonucleotide part comprises at least one modification, wherein said modification is selected from the group consisting of a backbone modification, a sugar modification and a base modification, when compared to an RNA-based oligonucleotide.
4. Compound according to claim 3, n said modification is selected from the group consisting of 2’-O-methyl phosphorothioate, morpholino phosphorodiamidate, locked c acid and peptide c acid.
5. Compound according to claim 2, wherein the oligonucleotide part is a 2’-O-methyl phosphorothioate oligonucleotide.
6. Compound according to any one of claims 1 to 5 , wherein said oligonucleotide part comprises at least one 2,6-diaminopurine, 2-thiouracil, 2-thiothymine, 5- methyluracil, 5-methylcytosine, thymine, 7-deazaguanosine, and/or hypoxanthine.
7. Compound according to any one of claims 1 to 6, wherein 1-10 abasic rs are present at a free terminus of said oligonucleotide part.
8. Compound according to claim 7, wherein said abasic r is chosen from the group consisting of 1-deoxyribose, 1,2-dideoxyribose, and/or yO- methylribose.
9. Compound according to claim 7 or 8, wherein 4 monomers of 1-deoxyribose, 1,2- dideoxyribose, and/or 1-deoxyO-methylribose are present at the 3’ terminus of the oligonucleotide part.
10. Compound according to claim 9, n the oligonucleotide part is (NAG)7, in which N is C or 5-methylcytosine.
11. Compound according to any one of claims 1-10, wherein the peptide part is linked to the oligonucleotide via a linker comprising a thioether moiety.
12. Compound according to any one of claims 1 to 11 for treating, preventing and/or delaying a human genetic disorder myotonic which is dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington’s disease-like 2 caused by CUG repeat expansions in the transcripts of DM1/DMPK, SCA8 or JPH3 genes.
13. A pharmaceutically able composition comprising a compound as defined in any one of claims 1 to 11.
14. An in vitro method for the reduction of the number of s CUG in transcripts of gene DM1/DMPK, SCA8 or JPH3 in a cell comprising the administration of a compound as defined in any one of claims 1 to 11 or a pharmaceutically acceptable composition as defined in claim 13.
15. Use of a nd as defined in any one of claims 1 to 11 or a pharmaceutical composition as defined in claim 13 for the manufacture of a medicament for treating, ting and/or delaying dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington’s e-like 2 caused by expansion of CUG repeats in transcripts of the DM1/DMPK, SCA8 or JPH3 genes.
16. A compound according to claim 1, substantially as herein described or exemplified.
17. A composition according to claim 13, substantially as herein described or ified.
18. A method according to claim 14, substantially as herein described or exemplified.
19. A use according to claim 15, substantially as herein bed or exemplified.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ713390A NZ713390B2 (en) | 2011-04-22 | 2012-04-23 | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478096P | 2011-04-22 | 2011-04-22 | |
EP11163581.9 | 2011-04-22 | ||
EP11163581 | 2011-04-22 | ||
US61/478,096 | 2011-04-22 | ||
PCT/NL2012/050273 WO2012144906A1 (en) | 2011-04-22 | 2012-04-23 | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ616762A NZ616762A (en) | 2015-11-27 |
NZ616762B2 true NZ616762B2 (en) | 2016-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012246822B2 (en) | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1) | |
JP7459691B2 (en) | RNA regulatory oligonucleotides with improved characteristics for the treatment of neuromuscular disorders | |
AU2020257111B2 (en) | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy | |
ES2532634T3 (en) | Procedures and means for efficient skipping of exon 45 in the pre-mRNA of Duchenne muscular dystrophy | |
JP5665317B2 (en) | Antisense compound | |
NZ592446A (en) | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna | |
JP6928025B2 (en) | RNA-regulated oligonucleotides with improved features for the treatment of Duchenne and Becker muscular dystrophy | |
NZ616762B2 (en) | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) | |
NZ713390B2 (en) | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) | |
CN118202049A (en) | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application |